Study Title,Status,Date of publication,DOI,Affiliation,Country of 1st author,Source of funding,Registration,Registration database,Protocol,Number of database(s),Database(s) name(s),Database(s) structured,Type of database,Database(s) country(s),Aim of study,Causal contrast,Number of primary outcome(s),Name of primary outcome(s),Type of primary outcome(s),Number of interventional arm(s),Number of control(s),Medical speciality,Name of primary (first) intervention,Type of intervention,ATC class,Comparator type,Comparator name,Study design,Statistical design,Sample size,High-dimensional method,Validation study,Position of the 1st/main hdPS analysis,Number of data dimensions,Temporal window,Included dimensions,Other dimensions,Diagnoses coding system,Procedures coding system,Drugs coding system,Granularity of codes,Other granularity,Prevalence filter,Number of most prevalent codes,Recurrence assessment,Covariates prioritization method,Number of predefined covariates,Number of prioritized covariates,Inclusion of post-baseline predefined covariates,Model used for building PS,Other model,Trimming,PS score main use,PS score other use,Additional variables used for,Reported list of included hdPS variables,Main or first intervention effect model,"Intervention, nb of eligible patients","Control, nb of eligible patients",Exclusion of eligible patients in the analysis,Use of a flowchart,"Intervention, nb of patients analyzed","Control, nb of patients analyzed",Reporting of crude analysis,Diagnostics for differences,hdPS specific sensitivity analysis,hdPS specific diagnostics,Investigator excluded variables,Transparency of hdPS reporting,Comparison with other methods (non hdPS),Method details,"Other, details",Use of a reporting guideline,Availability of code,Availability of data,Statistical software used,Aim ROBINS,Results assessed ROBINS,Bias due to confounding,Bias in selection of participants,Bias in classification of interventions,Bias due to deviations from intended interventions,Bias due to missing data,Bias in measurement of outcomes,Bias in selection of the reported result,Overall bias
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer,Done,1/6/2015,10.1001/jamaoncol.2015.0387,Yes,Canada,Public,Not reported,,Mentioned but not available,1, National Cancer Data Repository (NCDR) + CPRD + HES + ONS,CPRD (+HES),Both linked,UK,Safety,ITT,1,prostate cancer-specific mortality,Time to event,1,1,Urology, 5α-Reductase Inhibitors,Pharmacological,G04CB,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,365,"Outpatient prescriptions,Outpatient diagnoses,Hospitalizations (all),Lab records (all)","general practice–related variables (such as diagnoses, laboratory tests, and immunizations) / drug prescriptions /  hospitalizations.","Read Codes,ICD-10",,Other,,,,,Schneeweiss citation,Schneeweiss citation,11,50,No,Logistic regression,,Yes,Adjustment on deciles (stratification),,No additional variables used with/before/after hdPS,No,Cox regression,574,13318,Yes,Yes,574,12848,Yes,C-statistic,,,Yes,"Specify data dimensions,Specify software,Specify total number of covariates included",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.90,Moderate,Low,Low,Low,Low,Low,NI,Moderate
A Comparison of Confounding Adjustment Methods for Assessment of Asthma Controller Medication Effectiveness,Done,23/1/2014,10.1093/aje/kwt323,Yes,USA,Public,Not reported,,Not reported,2,TennCare / Commercial Health Plans,"Medicaid or Medicare,Other US commercial",PCD,USA,Efficacy,Per-protocol,1,"Composite of asthma-related ED visit, asthma-related hospitalization, dispensing of an oral corticosteroid",Time to event,1,1,Pulmonary Medicine,leukotriene antagonists,Pharmacological,R03DC,Active comparator,inhaled corticosteroids,New-user design,Not reported,Not reported,hdPS,No,Secondary analysis,7,,"Inpatient diagnoses,Inpatient procedures (including tests),Outpatient diagnoses,Outpatient procedures (including tests),Outpatient drug dispensation",ED diagnosis / ED procedures,,Not reported,Not reported,,,,,Schneeweiss citation,Association with outcome,13,,No,Logistic regression,,No,Adjustment,,No additional variables used with/before/after hdPS,No,Cox regression,1286,13505,Unclear,No,,,No,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify software",Yes,"Propensity score with predefined variables,Multivariable analysis on predefined variables",,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.26,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride,Done,22/5/2018,10.1186/s12891-018-2076-9,Yes,Canada,Public,Not reported,,Not reported,1,ICES,Ontario health databases,PCD,Canada,Safety,Per-protocol,1,new diagnosis of osteoporosis,Time to event,1,1,Rheumatology,dutasteride,Pharmacological,G04CB02,Active comparator,finasteride,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,7,1095,"Outpatient drug dispensation,Inpatient diagnoses,Medical encounters,Inpatient procedures (including tests)",emergency diagnoses / emergency procedures ,,,,,,Yes,200,Schneeweiss citation,Schneeweiss citation,5,500,No,Schneeweiss citation,,Not reported,Matching,,To adjust after hdPS matching/weighting,No,Cox regression,,,Unclear,No,,,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",Yes,Negative controls,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.90,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Acute renal failure in patients treated with dronedarone or amiodarone: a large population-based cohort study in Italy,Done,15/7/2015,10.1007/s00228-015-1903-2,Unclear,Italy,Public,Not reported,,Not reported,2,Lombardy claims database / Emilia-Romagna claims database,Other,PCD,Italy,Safety,ITT,1,acute renal failure,Time to event,1,1,Cardiology,Dronedarone,Pharmacological,C01BD07,Active comparator,Amiodarone,New-user design,Not reported,Not reported,hdPS,No,Secondary analysis,,240,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,,,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,1761,54978,Yes,Yes,,,Yes,Not reported,,,Not reported,Specify software,Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.83,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population,Done,22/8/2012,10.1111/j.1464-5491.2012.03772.x,Yes,Canada,Public,Not reported,,Not reported,1,OHIP + DAD + RPD + NACRS,Ontario health databases,PCD,Canada,Safety,ITT,1,Compose of death from any cause or hospitalization for acute myocardial infarction or congestive heart failure,Time to event,1,1,Diabetology,Glyburide,Pharmacological,A10BB01,Active comparator,Gliclazide,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,7,1095,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests)","physician claims, emergency diagnoses and procedures",ICD-10,Not reported,Not reported,,,Yes,200,Schneeweiss citation,Schneeweiss citation,,500,No,Schneeweiss citation,,Not reported,Matching,,"To match with the hdPS,To adjust after hdPS matching/weighting",No,Cox regression,4554,1386,Yes,No,1690,984,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included",Yes,Negative controls,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),HR 1.01,Moderate,Serious,Low,Low,NI,Low,NI,Serious
Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events  in Women of Advanced Age,Done,3/6/2019,10.1161/HYPERTENSIONAHA.119.13289,Yes,Canada,Public,Not reported,,Not reported,1,Institute for Clinical Evaluative Sciences,Ontario health databases,PCD,Canada,Safety,"ITT,Per-protocol",1,hypotension and hypotension-related events,Time to event,1,1,Nephrology,Alpha-Blocker,Pharmacological,C02CA,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Medical encounters",,"ICD-10,ICD-9",,Generic drug names,"3 digit ICD,Generic drug name",,,,Schneeweiss citation,Bross formula,,201,No,Schneeweiss citation,,Not reported,Matching,,To match with the hdPS,Yes,Cox regression,14222,720685,Yes,Yes,14106,14106,No,Standardized Difference,,,Not reported,"Specify data dimensions,Description parameters for feature generation,Specify covariate priorisation method,Specify software,Specify total number of covariates included",No,,,RECORD,Not reported,Not reported,SAS,Assignment (ITT),HR 1.10,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Analyzing intent-to-treat and per-protocol effects on safety outcomes using a medical information database: an application to the risk assessment of antibiotic-induced liver injury,Done,25/9/2018,10.1080/14740338.2018.1528224,Yes,Japan,Public,Not reported,,Not reported,1,University of Tokyo Hospital,Other,Hospital database,Japan,Safety,"ITT,Per-protocol",1,liver injury,Time to event,1,1,Infectious Disease Medicine,macrolides,Pharmacological,J01FA ,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,2,,"Inpatient prescriptions,Inpatient diagnoses",,ICD-10,,Other,"3 digit ICD,Other",4 digits NHIDC,Yes,100,"""Once, sporadic, frequent""",Bross formula,4,100,No,Logistic regression,,Yes,Weighting,Adjustment on deciles (stratification),No additional variables used with/before/after hdPS,No,Cox regression,11396,53213,Yes,Yes,,,Yes,"C-statistic,Standardized Difference",,PS distribution plots,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.22,Moderate,Serious,Low,Low,NI,Serious,NI,Serious
Antibiotic Exposure in the First Year of Life and the Risk of Attention-Deficit/ Hyperactivity Disorder: A Population-Based Cohort Study,Done,1/11/2019,10.1093/aje/kwz178,Yes,Canada,Public,Not reported,,Not reported,1,Manitoba Population Research Data Repository,Other canadian databases,EMR / Registry,Canada,Safety,ITT,1,ADHD diagnosis,Time to event,1,1,Infectious Disease Medicine,Antibiotic- Exposed,Pharmacological,J01,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,10,365,"Inpatient diagnoses,Inpatient procedures (including tests),Outpatient diagnoses,Outpatient procedures (including tests),Outpatient drug dispensation",,,,,,,Yes,200,"""Once, sporadic, frequent""",Bross formula,15,500,No,Schneeweiss citation,,Not reported,Matching,,To match with the hdPS,No,Cox regression,84424,103181,Yes,Yes,34869,34869,Yes,Standardized Difference,,,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Other,sibling cohort,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.02,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn,Done,2/6/2015,10.1001/jama.2015.5605,Yes,USA,Public,Not reported,,Not reported,1,Medicaid,Medicaid or Medicare,PCD,USA,Safety,ITT,1,Persistent pulmonary hypertension of the newborn,Binary,2,1,Psychiatry,SSRI,Pharmacological,N06AB,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,31,200,Unclear,Logistic regression,,Yes,Stratification,,No additional variables used with/before/after hdPS,No,Logistic regression,102179,3660380,Yes,No,65316,657515,Yes,"Standardized Difference,C-statistic",,,Yes,"Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),OR 1.10,Serious,Serious,Low,Serious,NI,Low,NI,Serious
Antidepressants and the risk of death in older patients with depression: A population-based cohort study,Done,15/4/2019,10.13 71/journal.pone.0215289,Yes,Germany,Public,Not reported,,Not reported,1,GePaRD,GePaRD,PCD,Germany,Safety,Per-protocol,1,Death,Time to event,12,1,Psychiatry,escitalopram,Pharmacological,N06A,Active comparator,citalopram,New-user design,Not reported,Not reported,hdPS,No,Sensitivity analysis,6,,"Outpatient drug dispensation,Medical encounters,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient procedures (including tests)",,ICD-10,,ATC,,,,,Schneeweiss citation,Schneeweiss citation,57,500,No,Schneeweiss citation,,Yes,Adjustment,,No additional variables used with/before/after hdPS,No,Cox regression,,,,,,,No,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",Yes,Multivariable analysis on predefined variables,,Not reported,Not reported,On demand,SAS,Starting and adhering (PP),HR 0.96,Moderate,Low,Low,Serious,NI,Low,NI,Serious
"Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study",Done,13/5/2015,10.1136/bmj.h2298,Yes,Canada,Public,Not reported,,Mentioned but not available,1,ICES (MOMBABY + ODB + RPDB + CIHI-DAD + OMHRS + NACRS + OHIP),Ontario health databases,Both linked,Canada,Safety,ITT,6,Gestational diabetes,Discrete,1,1,Psychiatry,Antipsychotics,Pharmacological,N05A,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,8,365,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests)",,"ICD-10,Other",Not reported,Not reported,Other,2 digits ICD,Yes,200,"""Once, sporadic, frequent""",Association with exposure,,500,No,Schneeweiss citation,,Not reported,Matching,,"To match with the hdPS,To adjust after hdPS matching/weighting",Yes,Poisson regression,1209,40314,Yes,No,1021,1021,Yes,Standardized Difference,,Inspection of selected variables,Yes,"Specify data dimensions,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.10,Moderate,Serious,Low,Low,NI,Low,NI,Serious
Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer,Done,27/12/2017,10.1093/annonc/mdx822,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Safety,Per-protocol,1,incident colorectal cancer,Time to event,1,1,Oncology,Aromatase inhibitor,Pharmacological,L02BG,Active comparator,tamoxifen,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient prescriptions,Outpatient diagnoses,Outpatient procedures (including tests),Administrative data",administrative / disease history,,,,,,,,Schneeweiss citation,Schneeweiss citation,13,500,No,Schneeweiss citation,,Yes,Adjustment,,No additional variables used with/before/after hdPS,No,Cox regression,12278,12115,Unclear,No,9701,8893,No,Not reported,,,Not reported,"Specify total number of covariates included,Specify data dimensions,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.90,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
"Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach",Done,9/6/2021,10.1053/ j.ajkd.2021.03.030,Yes,USA,Public,Not reported,,Not reported,1,US Renal Data + Medicare,Medicaid or Medicare,Both linked,USA,Both,ITT,4,All-cause mortality / all-cause hospitalization / cause-specific hospitalization / sepsis,Time to event,1,1,Nephrology,Arteriovenous fistula,Not-pharmacological,,Active comparator,Arteriovenous graft,New-user design,Not reported,Not reported,hdPS,Yes,Primary analysis,6,730,"Outpatient diagnoses,Inpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests)",,ICD-9,CPT,,,,Yes,300,"""Once, sporadic, frequent""",Bross formula,31,500,No,Logistic regression,,Yes,Weighting,,No additional variables used with/before/after hdPS,No,Cox regression,15905,3962,Yes,Yes,,,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Other,IV,Not reported,Not reported,Not reported,"Stata,R",Assignment (ITT),HR 0.82,Moderate,Low,Low,Low,Moderate,Low,NI,Moderate
Association between perioperative beta blocker use and cancer survival following surgical resection,Done,17/5/2018,10.1016/j.ejso.2018.05.012,Yes,Canada,Public,Not reported,,Mentioned but not available,1,ICES,Ontario health databases,PCD,Canada,Efficacy,ITT,2,all-cause mortality / cancer-specific mortality,Time to event,1,1,Surgical Oncology,beta-blocker,Pharmacological,C07A,Active comparator,other hypertensive treatment ,Prevalent user,Not reported,Not reported,hdPS,No,Primary analysis,,,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,3,,Unclear,Schneeweiss citation,,Not reported,Matching,,To adjust after hdPS matching/weighting,No,Cox regression,,,Yes,No,,,Yes,Standardized Difference,,,Not reported,Specify software,No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.99,Serious,Low,Low,Low,NI,Low,NI,Serious
Association between perioperative oral care and postoperative pneumonia after cancer resection: conventional versus high-dimensional propensity score matching analysis,Done,18/12/2018,10.1007/s00784-018-2783-5,Yes,Japan,Public,Not reported,,Mentioned but not available,1,Japan Medical Data Centre,Other,PCD,Japan,Efficacy,Per-protocol,2,Postoperative pneumonia / Procedure-related complications ,Binary,1,1,Odontology,Perioperative oral care,Not-pharmacological,,Standard care,Unexposed,Prevalent user,Not reported,Yes,hdPS,No,Primary analysis,5,365,"Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient procedures (including tests),Drugs (all)",,ICD-10,Other,Other,,,,,Schneeweiss citation,Bross formula,5,500,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Logistic regression,621,4374,Yes,Yes,574,574,Yes,Standardized Difference,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,R,Starting and adhering (PP),RD -0.3,Moderate,Serious,Low,Low,NI,Low,NI,Serious
Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children,Done,16/3/2020,10.1001/jamapediatrics.2020.0007,Yes,Sweden,Public,Not reported,,Not reported,1,Swedish registers,Other,EMR / Registry,Sweden,Safety,ITT,1,First diagnosis of fracture requiring hospitalization or acute care,Time to event,1,1,Gastroenterology,PPI,Pharmacological,A02BC,Standard care,Unexposed,New-user design,Not reported,No,hdPS,No,Sensitivity analysis,3,730,"Outpatient drug dispensation,Diagnoses (all),Disease specific",surgery procedures,ICD-10,Other,ATC,"3 digit ICD,Other",5 digit ATC / 5 digit Swedish surgery codes,Yes,200,"""Once, sporadic, frequent""",Bross formula,38,200,No,Logistic regression,,No,Matching,,No additional variables used with/before/after hdPS,Yes,Cox regression,117234,2373292,Yes,Yes,115655,115655,No,Standardized Difference,,Surveillance for IVs,Yes,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.10,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children,Done,18/4/2017,10.1001/jama.2017.3415,Yes,Canada,Public,Not reported,,Not reported,1,ICES + MOMBABY,Ontario health databases,Both linked,Canada,Safety,ITT,1,identify autism spectrum disorder,Binary,1,1,Psychiatry,Serotonergic antidepressant,Pharmacological,N06AB,Standard care,Unexposed,New-user design,Not reported,No,hdPS,No,Primary analysis,8,365,"Outpatient drug dispensation,Outpatient diagnoses,Medical encounters,Inpatient diagnoses,Inpatient procedures (including tests),Disease specific",psychiatric diagnoses / emergency department diagnoses and procedures,Other,Other,Generic drug names,"Generic drug name,Other",,Yes,200,"""Once, sporadic, frequent""",Bross formula,8,500,No,Schneeweiss citation,,Not reported,Weighting,,,Yes,Cox regression,2837,33069,Unclear,No,,,No,Standardized Difference,,,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,"Multivariable analysis on predefined variables,Other",sibling analysis,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.61,Moderate,Serious,Low,Low,NI,Low,NI,Serious
Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation,Done,25/11/2019,10.1001/jamainternmed.2019.5679,Yes,USA,Public,Not reported,,Not reported,1,MarketScan,Truven Marketscan,PCD,USA,Safety,"ITT,Per-protocol",3,hip fractures,Time to event,5,1,Cardiology,DOAC,Pharmacological,B01AF,Active comparator,warfartin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests),Inpatient diagnoses",,ICD-9,Not reported,Not reported,,,Yes,200,Schneeweiss citation,Bross formula,43,500,No,Logistic regression,,Not reported,Matching,,To match with the hdPS,No,Cox regression,,,Yes,Yes,,,No,Not reported,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,STROBE,Not reported,Not reported,SAS,Assignment (ITT),HR 0.91,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Association of Early Post-Discharge Follow-Up by a Primary Care Physician and 30-Day Rehospitalization Among Older Adults,Done,2/12/2014,10.1007/s11606-014-3106-4,Unclear,USA,Public,Not reported,,Not reported,1,primary hospital database,Other,Hospital database,USA,Efficacy,ITT,1,rehospitalization within 30 days of discharge from the index hospitalization,Time to event,1,1,General Practice,PCP office visit,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests)",,,,,,,,,Schneeweiss citation,Schneeweiss citation,,,Unclear,Schneeweiss citation,,Yes,Stratification,Matching,No additional variables used with/before/after hdPS,No,Cox regression,1000,2661,Yes,No,852,852,Yes,C-statistic,,,Not reported,"Specify data dimensions,Specify software",Yes,Multivariable analysis on predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.96,Moderate,Serious,Low,Low,NI,Low,NI,Serious
Association of Hospitalization With First-Line Antidepressant Polypharmacy Among Veterans of Iraq and Afghanistan With Post-Traumatic Stress Disorder: Examining the Influence of Methodological Approaches,Done,1/10/2016,10.7205/MILMED-D-15-00327,Yes,USA,Public,Not reported,,Not reported,1,VA medical center,Veterans Administration databases,PCD,USA,Safety,Unclear,1,all-cause (psychiatric or medical) hospital admission,Binary,1,1,Psychiatry,Polypharmacy + AD,Pharmacological,,Active comparator,Monotherapy with AD,Prevalent user,Not reported,Not reported,hdPS,No,Primary analysis,4,365,"Inpatient diagnoses,Inpatient procedures (including tests)",clinic type,ICD-9,CPT,,Other,5-digit ICD,Yes,10,"""Once, sporadic, frequent""",Bross formula,5,30,No,Logistic regression,,Yes,Adjustment on deciles (stratification),Weighting,No additional variables used with/before/after hdPS,Yes,Logistic regression,307,91,Unclear,No,,,Yes,Not reported,Different total number of covariates,Sequential addition of variables plots,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Description parameters for feature generation,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",Yes,Multivariable analysis on predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 2.07,Moderate,Serious,Moderate,Serious,NI,Low,NI,Serious
Association of Low-Dose Quetiapine and Diabetes,Done,7/5/2021,10.1001/jamanetworkopen.2021.3209,Yes,Denmark,Public,Not reported,,Not reported,1,Danish Registers,Other,EMR / Registry,Denmark,Safety,"Per-protocol,ITT",1,Incident type 2 diabetes,Time to event,1,1,Psychiatry,quetiapine,Pharmacological,N05AH04,Active comparator,SSRI,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,2,365,"Drugs (all),Diagnoses (all)",,ICD-10,,ATC,"3 digit ICD,Other",5 digits ATC,,,"""Once, sporadic, frequent""",Schneeweiss citation,3,50,No,Logistic regression,,No,Matching,Weighting,,Yes,Poisson regression,57701,838584,Yes,Yes,54616,54616,Yes,Standardized Difference,,,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify total number of covariates included,Specify software",Yes,Other,active assay sensitivity control exposure,RECORD-PE,Not reported,Not reported,Stata,Starting and adhering (PP),IRR 1.18,Serious,Low,Low,Serious,NI,Low,NI,Serious
Association of Neuraxial Labor Analgesia for Vaginal Childbirth With Risk of Autism Spectrum Disorder,Done,22/12/2021,10.1001/jamanetworkopen.2021.40458,Yes,USA,Public,Not reported,,Not reported,2,Medicaid Analytic eXtract (MAX) / IBM MarketScan,"Medicaid or Medicare,Truven Marketscan",PCD,USA,Safety,"Per-protocol,ITT",1,Autism Spectrum Disorder,Time to event,1,1,Obstetrics,neuraxial labor analgesia,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Secondary analysis,,365,Unclear,,ICD-9,,,,,,,Not reported,Not reported,69,200,Yes,Not reported,,Yes,Adjustment on deciles (stratification),,To adjust with hdPS (stratas or not),No,Cox regression,484752,425944,Yes,No,339326,298160,Yes,Standardized Difference,Different temporal windows,,Not reported,"Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",Yes,Propensity score with predefined variables,,STROBE,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.10,Serious,Low,Low,Low,NI,Low,NI,Serious
Association of Postdischarge Rehabilitation with Mortality inIntensive Care Unit Survivors of Sepsis,Done,11/9/2014,10.1164/rccm.201406-1170OC,Unclear,Taiwan,Not reported,Not reported,,Not reported,1,NHIRD,Other,PCD,Taiwan,Efficacy,ITT,1,mortality,Time to event,1,1,Physical Rehabilitation,Rehabilitation within 90 days,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,180,"Outpatient procedures (including tests),Drugs (all),Inpatient diagnoses,Outpatient diagnoses,Inpatient procedures (including tests),Disease specific","prescription, examination, procedures in outpatient or emergency / prescription, examination, procedure in hospitalization / ICD-9 outpatient codes / ICD-9 inpatient codes / prescription, examination, procedure in hospitalization for sepsis",ICD-9,Not reported,Not reported,3 digit ICD,,Yes,200,"""Once, sporadic, frequent""",Bross formula,14,500,No,Logistic regression,,Yes,Stratification,Matching,To match with the hdPS,Yes,Cox regression,16239,97820,Yes,Yes,15535,15535,Yes,Not reported,,PS distribution plots,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",Yes,Multivariable analysis on predefined variables," multivariable-adjusted Cox model including all sepsissurvivors among which postdischargerehabilitation was calculated as time-varying covariate, and testing the varioustime windows for rehabilitation afterhospital discharge (e.g., 45, 90, 180, and 365d); and (3) Cox model with sandwichestimator of hospital-level or with shared-frailty model of the individual hospitalidentifier to adjust for hospital-levelvariation in patterns of rehabilitationreferral. ",Not reported,Not reported,Not reported,SAS,Assignment (ITT),mortality HR 0.94,Moderate,Moderate,Low,Low,Low,Low,NI,Moderate
Atrial fibrillation is associated with greater risk of dementia in  older veterans,Done,1/11/2021,10.1016/j.jagp.2021.02.038,Yes,USA,Public,Not reported,,Not reported,1,Veterans Health Administration,Veterans Administration databases,PCD,USA,Safety,Per-protocol,1,Dementia,Discrete,1,1,Cardiology,Anticoagulation,Pharmacological,B01A,Active comparator,Unexposed,New-user design,Not reported,No,hdPS,No,Primary analysis,,1460,,,ICD-9,,,,,,,Schneeweiss citation,Schneeweiss citation,13,,Unclear,Schneeweiss citation,,Not reported,Adjustment on deciles (stratification),,,No,Logistic regression,16382,391489,No,No,16382,391489,No,Not reported,,,Not reported,Specify software,No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),OR 1.16,Serious,Serious,Low,Low,NI,Low,NI,Serious
Benzodiazepines and risk of all cause mortality in adults:   cohort study,Done,6/7/2017,10.1136/bmj.j2941,Yes,USA,Public,Not reported,,Not reported,1,Optum Clinformatics,Optum Clinformatics,PCD,USA,Safety,ITT,1,death,Time to event,1,1,Psychiatry,benzodiazepine,Pharmacological,N05BA,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,180,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,90,200,No,Schneeweiss citation,,Not reported,Matching,,,No,Cox regression,1686410,1930159,Yes,Yes,1252988,1252988,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,Not reported,,,SAS,Assignment (ITT),HR 1.00,Moderate,Low,Moderate,Low,NI,Low,NI,Moderate
Broad-Spectrum Antibiotic Use and Disease Progression in Early-Stage Melanoma Patients: A Retrospective Cohort Study,Done,29/8/2021,10.3390/cancers13174367,Unclear,USA,Public,Not reported,,Not reported,1,IQVIA PharMetrics,IQVIA PharMetrics,PCD,USA,Both,ITT,1,Melanoma progression,Time to event,3,1,Infectious Disease Medicine,Antibiotic in pre-3 month,Pharmacological,J01,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient procedures (including tests)",,ICD-10,HCPCS,Other,"3 digit ICD,Other",Level I and II HCPCS / 6 digits GPI,,,Schneeweiss citation,Bross formula,9,200,No,Logistic regression,,Yes,Weighting,,No additional variables used with/before/after hdPS,No,Cox regression,646,3284,Yes,Yes,,,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify covariate priorisation method,Description parameters for feature generation,Specify software",Yes,Negative controls,,STROBE,Not reported,No,SAS,Assignment (ITT),HR 0.81,Moderate,Low,Low,Low,NI,Moderate,NI,Moderate
Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study,Done,30/3/2019,10.1111/dom.13893,Yes,Canada,"Private,Public",Not reported,,Mentioned but not available,1,CPRD + HES + ONS,CPRD (+HES),Both linked,UK,Safety,"Per-protocol,ITT",5,myocardial infarction / ischaemic stroke / severe hypoglycemia / cardiovascular death / all-cause mortality,Time to event,1,2,Diabetology,glimepiride,Pharmacological,A10BB12,Active comparator,A10BB,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,10,500,No,Schneeweiss citation,,Yes,Matching,Weighting,To match with the hdPS,No,Cox regression,6438,25741,Yes,Yes,5944,20565,Yes,Standardized Difference,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,"SAS,R",Starting and adhering (PP),HR 0.99,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Comparative Effectiveness and Safety of  Standard or Reduced Dose Dabigatran vs.  Rivaroxaban in Nonvalvular Atrial Fibrillation,Done,30/10/2018,10.1002/cpt.1318,Yes,France,Private,Yes,EUPAS / CT.gov,Available,1,SNDS,SNDS,PCD,France,Both,Per-protocol,3,hospitalization with a main diagnosis of ischemic SSE / MB / all-cause death,Time to event,2,2,Cardiology,Dabigatran 150 mg,Pharmacological,B01AE07,Active comparator,Rivaroxaban 20 mg,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,1095,"Inpatient diagnoses,Outpatient drug dispensation,Medical encounters,Outpatient diagnoses",LTD,ICD-10,Other,ATC,3 digit ICD,,,,"""Once, sporadic, frequent""",Schneeweiss citation,24,500,No,Schneeweiss citation,,Not reported,Matching,Adjustment on deciles (stratification),No additional variables used with/before/after hdPS,Yes,Cox regression,15532,11195,No,Yes,7639,7639,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.92,Moderate,Low,Low,Serious,NI,Low,Moderate,Serious
Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice,Done,4/6/2019,10.1016/j.chest.2019.03.005,Yes,Canada,"Private,Public",Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Both,"Per-protocol,ITT",1,first moderate or severe COPD exacerbation,Time to event,1,1,Pulmonary Medicine,LABA-LAMA,Pharmacological,R03BB,Active comparator,Inhaled corticosteroids,New-user design,Not reported,,hdPS,No,Primary analysis,4,365,"Procedures (all),Drugs (all),Diagnoses (all),Symptoms",symptoms,Not reported,Not reported,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,,200,No,Schneeweiss citation,,Yes,Matching,,"To match with the hdPS,To adjust after hdPS matching/weighting",No,Cox regression,2066,54394,Yes,Yes,1977,1977,No,Not reported,,,Not reported,"Specify total number of covariates included,Specify software,Specify data dimensions",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.04,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation:  A retrospective cohort study,Done,13/4/2020,10.15586/jptcp.v27i2.662,Yes,Canada,Public,Not reported,,Not reported,1,PharmaNet + DAD + BCVS + LifeLabs,British Columbia health databases,PCD,Canada,Both,"ITT,Per-protocol",1,composite of ischemic stroke and systemic embolism / bleeding,Discrete,1,1,Cardiology,DOAC,Pharmacological,B01AF,Active comparator,VKA,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,1095,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Medical encounters",,ICD-10,Other,Generic drug names,,,Yes,200,Schneeweiss citation,Bross formula,36,500,No,Schneeweiss citation,,Yes,Adjustment,,To adjust with hdPS (stratas or not),No,Poisson regression,8535,11578,Yes,No,,,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,STROBE,Not reported,Not reported,SAS,Assignment (ITT),HR 1.15,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients,Done,15/9/2015,10.1097/MD.0000000000001751,Yes,Taiwan,Public,Not reported,,Not reported,1,NHIRD,Other,PCD,Taiwan,Both,"ITT,Per-protocol",3,all-cause mortality / hospitalization with heart failure / MACE (hospitalization with stroke or myocardial infarction),Time to event,1,1,Cardiology,angiotensin-converting enzyme inhibitors,Pharmacological,C09A,Active comparator,angiotensin II recep- tor blockers,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,,"Symptoms,Drugs (all),Procedures (all),Diagnoses (all),Administrative data",demographics / drug codes / laboratory and diagnostic procedures,ICD-9,Not reported,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,,500,No,Logistic regression,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,48501,31506,Yes,Yes,12347,12347,No,Standardized Difference,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),all-cause mortality HR 0.89,Moderate,Moderate,Moderate,Moderate,NI,Low,NI,Moderate
"Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study",Done,6/4/2020,10.1038/s41598-020-62318-y,No,USA,Not reported,Not reported,,Not reported,1,Austrian social security institutions,Other,PCD,Austria,Both,ITT,2,all-cause death / MACE,Time to event,17,17,Cardiology,Antihypertensive drugs branded,Pharmacological,C02,Active comparator,generics,New-user design,Not reported,Not reported,hdPS,Yes,Primary analysis,,180,,,,,,,,,,Schneeweiss citation,Bross formula,6,200,No,Other,LASSO,Not reported,Weighting,,,No,Cox regression,427641,558508,Unclear,No,,,Yes,General Weighted Difference,,,Not reported,"Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Multivariable analysis on predefined variables,,Not reported,Not reported,Not reported,R,Assignment (ITT),HR 1.15,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparative Effectiveness of Carotid Artery Stenting Versus Carotid Endarterectomy Among Medicare Beneficiaries,Done,21/3/2016,10.1161/CIRCOUTCOMES.115.002336,Yes,USA,Public,Not reported,,Not reported,2,Medicare + CARE Registry / Medicare + SVS-VR,Medicaid or Medicare,Both linked,USA,Both,ITT,3,death / stroke transient ischemic attack / periprocedural MI,Time to event,1,1,Cardiology,Carotid Artery Stenting,Not-pharmacological,,Active comparator,Carotid Endarterectomy,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,13,,"Outpatient procedures (including tests),Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests)",other diagnoses / other procedures / imaging results,,,,,,,,Schneeweiss citation,Schneeweiss citation,6,,No,Schneeweiss citation,,Not reported,Adjustment on deciles (stratification),,To adjust with hdPS (stratas or not),No,Cox regression,1999,3255,Unclear,No,,,Yes,C-statistic,,,Not reported,"Specify data dimensions,Specify software",No,,,STROBE,Not reported,Not reported,SAS,Assignment (ITT),HR 1.13,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparative effectiveness of dimethyl fumarate in multiple sclerosis,Done,29/8/2021,10.1111/bcp.15071,Yes,France,Private,Not reported,,Not reported,1,SNDS,SNDS,PCD,France,Efficacy,Per-protocol,1,annual rate of relapse subject to treatment (ARRt),Continuous,1,3,Neurology,dimethyl fumarate,Pharmacological,L04AX07,Active comparator,IMM,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,365,"Outpatient drug dispensation,Inpatient diagnoses,Medical encounters,Outpatient procedures (including tests),Lab records (all),Outpatient diagnoses","LTD registrations diagnoses, lab tests",ICD-10,Not reported,ATC,,,,,"""Once, sporadic, frequent""",Bross formula,18,,No,Logistic regression,,Yes,Matching,"Adjustment on deciles (stratification),Weighting",,Yes,Poisson regression,2697,2997,Yes,No,1780,1780,Yes,"Standardized Difference,C-statistic",,PS distribution plots,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify software,Describe feature recurrence assessment method",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),RR 0.72,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study,Done,18/12/2019,10.2147/COPD.S226324,Yes,Canada,Public,Not reported,,Not reported,6,Administrative data from 6 Canadian provinces CNODES,CNODES network databases,PCD,Canada,Efficacy,ITT,3,repeat ambulatory care visits for COPD / hospitalisation with COPD / subsequent antibiotic prescriptions,Time to event,1,1,Infectious Disease Medicine,fluoroquinolone,Pharmacological,J01MA,Active comparator,other antibiotics,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,,,Unclear,Schneeweiss citation,,Not reported,Weighting,,,No,Logistic regression,,,Unclear,Yes,,,No,Not reported,,,Not reported,,No,,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),OR 1.32,NI,Low,Low,Low,NI,Low,NI,NI
Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes,Done,3/8/2020,10.1111/dom.14169,Yes,UK,Private,Not reported,,Mentioned but not available,1,CPRD Gold + HES + ONS,CPRD (+HES),Both linked,UK,Efficacy,"ITT,Per-protocol",1,Time to HbA1c < 7,Time to event,1,1,Diabetology,gliclazide,Pharmacological,A10BB09,Active comparator,sitagliptin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,,"Other,Medical encounters,Outpatient prescriptions",,,,,,,,,Schneeweiss citation,Schneeweiss citation,36,300,,Logistic regression,,Yes,Matching,Weighting,No additional variables used with/before/after hdPS,No,Cox regression,1207,5479,Yes,Yes,993,993,No,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,RECORD-PE,Not reported,Not reported,Stata,Assignment (ITT),HR 1.35,Moderate,Low,Low,Low,Moderate,Low,NI,Moderate
Comparative Effectiveness of Intra-Articular Hyaluronic Acid and Corticosteroid Injections on the Time to Surgical Knee Procedures,Done,14/7/2017,10.1016/j.arth.2017.07.007,Unclear,USA,Public,Not reported,,Available,1,LifeLink,IQVIA PharMetrics,PCD,USA,Efficacy,ITT,1,receipt of a knee OA surgical intervention,Time to event,1,2,Orthopedics,Hyaluronic Acid,Pharmacological,M09AX01,Active comparator,corticosteroid,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,180,"Inpatient diagnoses,Inpatient procedures (including tests),Outpatient diagnoses,Outpatient procedures (including tests),Outpatient drug dispensation",,Other,"CPT,HCPCS",Other,Other,,Yes,200,"""Once, sporadic, frequent""",Bross formula,52,500,No,Logistic regression,,Not reported,Matching,,,Yes,Cox regression,797,5327,No,No,,,Yes,Standardized Difference,,,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify software,Specify total number of covariates included",Yes,"Multivariable analysis on predefined variables,Negative controls",,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.89,Serious,Moderate,Moderate,Moderate,NI,Low,NI,Serious
Comparative effectiveness of LABA-ICS versus LAMA as  initial treatment in COPD targeted by blood eosinophils:  a population-based cohort study,Done,17/10/2018,10.1016/ S2213-2600(18)30368-0,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Efficacy,ITT,1,COPD exacerbation,Time to event,1,1,Pulmonary Medicine,LABA ICS,Pharmacological,R03BB04,Active comparator,LAMA,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,365,"Lab records (all),Procedures (all),Diagnoses (all),Drugs (all),Symptoms,Administrative data",clinical / administrative,Not reported,Not reported,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,3,500,No,Logistic regression,,Yes,Matching,,To adjust after hdPS matching/weighting,No,Cox regression,18500,13870,Yes,Yes,12366,12366,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.95,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparative effectiveness of novel oral  anticoagulants in UK patients with non- valvular atrial fibrillation and chronic  kidney disease: a matched cohort study,Done,22/11/2017,10.1136/bmjopen-2017-019638,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Efficacy,"Per-protocol,ITT",1,composite of ischaemic stroke and systemic embolism,Time to event,1,1,Cardiology,NOAC,Pharmacological,B01A,Active comparator,VKAs,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,365,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,2,500,No,Not reported,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,10787,23306,Yes,Yes,6731,6731,No,Not reported,,,Not reported,"Specify software,Specify total number of covariates included",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.94,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation,Done,6/7/2017,10.1186/s12872-017-0672-5,Yes,USA,Public,Not reported,,Not reported,1,MarketScan,Truven Marketscan,PCD,USA,Both,ITT,5,ischemic / stroke / intracranial bleeding / MI / GI bleeding,Time to event,2,1,Cardiology,rivaroxaban,Pharmacological,B01AF01,Active comparator,warfarin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests)",,,,,,,Yes,200,Schneeweiss citation,Schneeweiss citation,35,500,No,Schneeweiss citation,,Not reported,Matching,,,No,Cox regression,32495,45496,Yes,No,39011,83981,No,Not reported,,PS distribution plots,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.75,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparative Effectiveness of Tiotropium and Ipratropium in Prevention of Hospital Readmission for COPD: A Population-Based Cohort Study,Done,1/4/2013,10.1016/j.clinthera.2012.10.007,Yes,Canada,Public,Not reported,,Not reported,1,British Columbia Databases,British Columbia health databases,PCD,Canada,Both,ITT,1,Hospital Readmission for COPD,Time to event,1,1,Pulmonary Medicine,Tiotropium,Pharmacological,R03BB04 ,Active comparator,Ipratropium,New-user design,Not reported,Yes,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient diagnoses",,"ICD-10,ICD-9",,ATC,Other,ATC5,Yes,200,Schneeweiss citation,Bross formula,7,500,No,Logistic regression,,Not reported,Matching,,To match with the hdPS,No,Cox regression,992,2731,Yes,Yes,750,750,Yes,C-statistic,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.97,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparative Real‑Life Effectiveness and Safety of Dabigatran  or Rivaroxaban vs. Vitamin K Antagonists: A High‑Dimensional  Propensity Score Matched New Users Cohort Study in the French  National Healthcare Data System SNDS,Done,29/6/2019,10.1007/s40256-019-00359-z,Yes,France,Private,Yes,EUPAS / CT.GOV,Available,1,SNDS,SNDS,PCD,France,Both,Per-protocol,1,hospitalization with a main  diagnosis of SSE / major bleeding / all-cause death,Time to event,2,1,Cardiology,dabigatran,Pharmacological,B01AE07,Active comparator,VKA,New-user design,Not reported,No,hdPS,No,Primary analysis,4,1095,"Outpatient drug dispensation,Inpatient diagnoses,Medical encounters,Outpatient diagnoses",Chronic disease,ICD-10,,ATC,"3 digit ICD,Other",ATC-7,,,"""Once, sporadic, frequent""",Association with outcome,11,500,No,Logistic regression,,Not reported,Matching,Adjustment on deciles (stratification),No additional variables used with/before/after hdPS,Yes,Cox regression,27060,44653,Yes,No,20489,23053,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",Yes,Negative controls,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0398,Moderate,Low,Low,Serious,NI,Low,Moderate,Serious
Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study,Done,2/7/2016,10.1016/j.euroneuro.2016.07.006,Yes,Germany,Public,Not reported,,Not reported,1,GePaRD,GePaRD,PCD,Germany,Safety,ITT,1,death,Time to event,14,1,Psychiatry,Melperone,Pharmacological,N05A,Active comparator,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Sensitivity analysis,5,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests)",,,,,,,,,Schneeweiss citation,Schneeweiss citation,73,500,No,Schneeweiss citation,,Not reported,Adjustment,,No additional variables used with/before/after hdPS,No,Cox regression,56904,26632,Unclear,No,,,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.13,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemic,Done,14/3/2016,10.1016/j.diabres.2016.03.006,Yes,USA,Public,Not reported,,Not reported,1,Medicaid,Medicaid or Medicare,PCD,USA,Safety,Per-protocol,1,severe hypoglycemia,Binary,7,1,Diabetology,Atorvastatin,Pharmacological,C10AA,Active comparator,Pravastatin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,9,,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient prescriptions",other settings procedures / diagnoses,ICD-9,"CPT,HCPCS",Generic drug names,"3 digit ICD,5 digit CPT,Generic drug name",,Yes,200,None,Bross formula,18,665,No,Logistic regression,,Not reported,Adjustment,,No additional variables used with/before/after hdPS,Yes,Cox regression,109371,21066,Unclear,No,,,Yes,Not reported,,"Inspection of selected variables,Surveillance for IVs",Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.94,Moderate,Low,Low,Moderate,NI,Moderate,NI,Moderate
Comparative Safety of Dipeptidyl  Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes,Done,11/10/2018,10.1038/s41598-018-33483-y,Unclear,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Safety,Per-protocol,1,"time to acute kidney injury, acute respiratory tract infection or acute pancreatitis",Time to event,1,4,Diabetology,DPP4i,Pharmacological,A10BH,Active comparator,A10BB,New-user design,Not reported,Yes,hdPS,No,Primary analysis,,365,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,15,40,No,Logistic regression,,Yes,Adjustment on deciles (stratification),Matching,To adjust with hdPS (stratas or not),No,Cox regression,8422,29793,Yes,Yes,8411,28990,Yes,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,R,Starting and adhering (PP),HR ,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Sudden  Cardiac Arrest Ventricular Arrhythmia: Population-Based Cohort  Studies,Done,31/7/2021,10.1002/cpt.2381.,Yes,USA,Public,Not reported,,Not reported,2,Medicaid / Optum,"Medicaid or Medicare,Optum Clinformatics",PCD,USA,Safety,Per-protocol,1,SCA-VA events,Time to event,2,1,Diabetology,saxagliptin,Pharmacological,A10BH03,Active comparator,sitagliptin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,9,365,"Outpatient drug dispensation,Outpatient procedures (including tests),Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests)",,"ICD-10,ICD-9","CPT,HCPCS",Generic drug names,"3 digit ICD,Generic drug name,Other",4 digit CPT / 2 digit ICD9,Yes,200,None,Bross formula,72,500,No,Logistic regression,,No,Matching,Weighting,To adjust after hdPS matching/weighting,Yes,Cox regression,23902,150460,Yes,No,23895,96972,No,Standardized Difference,,"Inspection of selected variables,Surveillance for IVs,PS distribution plots",Yes,"Specify data dimensions,Description parameters for feature generation,Specify covariate priorisation method,Describe feature recurrence assessment method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 2.01,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia,Done,18/11/2017,10.2337/dc17-0294,Yes,USA,Public,Not reported,,Not reported,1,Medicaid,Medicaid or Medicare,PCD,USA,Safety,Per-protocol,1,SCA/VA event,Time to event,2,1,Diabetology,glyburide,Pharmacological,A10BB01,Active comparator,glipizide,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,9,365,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests),Other",,ICD-9,CPT,Generic drug names,"3 digit ICD,5 digit CPT,Other",,Yes,200,None,Bross formula,61,500,No,Logistic regression,,Not reported,Adjustment,,To adjust with hdPS (stratas or not),Yes,Cox regression,202148,2019604,Yes,No,,,Yes,Standardized Difference,,Surveillance for IVs,Yes,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.82,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis,Done,9/6/2015,10.1111/jep.12389,Yes,USA,Not reported,Not reported,,Not reported,1,Medicare,Medicaid or Medicare,PCD,USA,Efficacy,Per-protocol,1,Fracture,Time to event,1,1,Rheumatology,Biphosphonate,Pharmacological,M05BA,Active comparator,Teriparatide,New-user design,Not reported,Not reported,hdPS,No,Sensitivity analysis,5,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests)",Diagnosis Related Group,ICD-9,"HCPCS,Other",Generic drug names,"3 digit ICD,Generic drug name",,Yes,200,Schneeweiss citation,Bross formula,11,500,No,Schneeweiss citation,,Not reported,Adjustment,Matching,No additional variables used with/before/after hdPS,Yes,Cox regression,39493,550,Yes,No,1695,467,No,Standardized Difference,,,Not reported,"Specify data dimensions,Description parameters for feature generation,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,"Propensity score with predefined variables,Multivariable analysis on predefined variables",,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.37,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Comparing the high-dimensional propensity score for use with administrative data with propensity scores derived from high-quality clinical data,Done,11/4/2019,10.1177/096228021984236,Yes,Canada,Public,Not reported,,Not reported,1,OHIP,Ontario health databases,PCD,Canada,Both,ITT,1,Mortality,Time to event,1,1,Cardiology,ACE inhibitor,Pharmacological,C09A,Active comparator,Beta blockers,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,365,"Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient drug dispensation",,"ICD-10,ICD-9",Other,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,16,,No,Schneeweiss citation,,Not reported,Weighting,,No additional variables used with/before/after hdPS,No,Cox regression,,,Unclear,No,,,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.95,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin,Done,15/9/2020,10.1001/jamanetworkopen.2020.16864,No,USA,Not reported,Not reported,,Not reported,1,Truven Health Analytics MarketScan,Truven Marketscan,PCD,USA,Safety,ITT,1,"Primary diagnosis for arrhythmia, palpitation, long QT, cardiac arrest, syncope or death",Binary,1,1,Infectious Disease Medicine,Amoxicillin,Pharmacological,J01CA04,Active comparator,Azithromycin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,365,"Outpatient diagnoses,Outpatient procedures (including tests),Outpatient drug dispensation",,ICD-9,,,,,,,Schneeweiss citation,Association with exposure,12,500,No,Schneeweiss citation,,Not reported,Matching,,,No,Logistic regression,,,Yes,No,2141285,2141285,No,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software,Specify covariate priorisation method",No,,,STROBE,Not reported,Not reported,SAS,Assignment (ITT),OR 1.08,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia,Done,29/11/2021,10.1001/jamanetworkopen.2021.36372,Yes,Australia,Public,Not reported,,Not reported,1,New South Wales ,Other,Both linked,Australia,Safety,"Per-protocol,ITT",1,MACE,Time to event,2,2,Addiction Medicine,Varenicline,Pharmacological,N07BA03,Active comparator,Bupropion,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,1825,Unclear,,ICD-10,,ATC,,,,,Schneeweiss citation,Schneeweiss citation,33,500,No,Schneeweiss citation,,Yes,Weighting,,No additional variables used with/before/after hdPS,No,Cox regression,342360,10467,Yes,Yes,342064,10457,No,Standardized Difference,,PS distribution plots,Not reported,"Specify total number of covariates included,Specify software,Describe results of diagnostics and sensitivity analysis",No,,,STROBE,Not reported,Not reported,Stata,Starting and adhering (PP),HR 0.87,Moderate,Low,Low,Moderate,NI,Low,NI,Serious
Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function,Done,15/9/2021,10.1001/jamanetworkopen.2021.23365,Yes,Canada,Public,Not reported,,Not reported,1,ICES,Ontario health databases,PCD,Canada,Both,"Per-protocol,ITT",4,adverse kidney events,Time to event,1,1,Nephrology,Chlorthalidone,Pharmacological,C03BA04,Active comparator,Hydrochlorothiazide,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,,"Outpatient diagnoses,Medical encounters,Outpatient drug dispensation,Inpatient diagnoses,Inpatient procedures (including tests)",Emergency diagnosis,ICD-10,Other,Generic drug names,"3 digit ICD,Generic drug name,Other",,,,Schneeweiss citation,Schneeweiss citation,,201,,Schneeweiss citation,,Not reported,Matching,,To match with the hdPS,Yes,Fine-Gray,3344,79211,Yes,Yes,2936,9786,No,Standardized Difference,,Inspection of selected variables,Yes,"Specify data dimensions,Description parameters for feature generation,Specify total number of covariates included,Specify software",No,,,STROBE,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.24,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Comparison of Different Approaches to Confounding Adjustment in a Study on the Association of Antipsychotic Medication With Mortality in Older Nursing Home Patients,Done,26/5/2011,10.1093/aje/kwr213,Yes,USA,Public,Not reported,,Not reported,1,Medicaid + Medicare + Minimum Data Set (MDS) + OSCAR,Medicaid or Medicare,PCD,USA,Safety,"ITT,Per-protocol",1,Death from any cause,Time to event,1,1,Psychiatry,Conventional antipsychotic,Pharmacological,N05,Active comparator,Atypical antipsychotic,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,180,"Outpatient drug dispensation,Disease specific,Procedures (all),Diagnoses (all)",diagnoses / procedures / MDS characteristics / OSCAR characteristics,ICD-9,Not reported,Not reported,,,Yes,200,Schneeweiss citation,Schneeweiss citation,32,500,No,Schneeweiss citation,,Yes,Adjustment on deciles (stratification),,No additional variables used with/before/after hdPS,No,Logistic regression,7252,74760,Yes,No,,,Yes,Not reported,Different dimensions,,Not reported,"Specify data dimensions,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis",Yes,"Propensity score with predefined variables,Multivariable analysis on predefined variables",,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),RR 1.39,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Comparison of Long-Term Risk Adverse Outcomes In Patients with Atrial Fibrillation Having Ablation vs Antiarrhythmic Medications,Done,15/2/2020,10.1016/j.amjcard.2019.11.004.,Yes,USA,Public,Not reported,,Not reported,1,Kaiser Permanente Northern California and Southern California,Kaiser Permanente,Both linked,USA,Both,ITT,5,death,Time to event,1,1,Cardiology,catheter ablation,Not-pharmacological,,Active comparator,antiarrhythmic therapy,Prevalent user,Not reported,Not reported,hdPS,No,Primary analysis,3,1825,"Diagnoses (all),Drugs (all),Procedures (all)",,Not reported,Not reported,Not reported,,,Yes,200,Schneeweiss citation,Schneeweiss citation,,300,No,Schneeweiss citation,,Not reported,Matching,,To match with the hdPS,No,Logistic regression,811,156963,Yes,Yes,535,1070,No,C-statistic,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.24,Moderate,Serious,Low,Low,NI,Low,NI,Serious
"Comparison of Low-, Moderate-, and High-Molecular-Weight Hyaluronic Acid Injections in Delaying Time to Knee Surgery",Done,2/5/2017,10.1016/j.arth.2017.04.041,Yes,USA,Public,Not reported,,Mentioned but not available,1,LifeLink Plus,IQVIA PharMetrics,PCD,USA,Efficacy,ITT,1,composite surgical intervention,Time to event,2,1,Orthopedics,LMWHA,Pharmacological,M09AX01,Active comparator,HMWHA,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,180,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,,500,Unclear,Schneeweiss citation,,Not reported,Matching,,,Yes,Cox regression,8526,12410,Unclear,,,,Yes,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",Yes,"Multivariable analysis on predefined variables,Negative controls",,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.939,Moderate,Low,Low,Low,NI,Low,NI,Moderate
"Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort",Done,23/4/2021,10.1001/jamanetworkopen.2021.5329,Yes,Canada,Public,Not reported,,Mentioned but not available,7,Canadian provinces (5) health data / MarketScan / CPRD,"CNODES network databases,Truven Marketscan,CPRD (+HES)","PCD,EMR / Registry",Canada / USA / UK,Safety,ITT,1,Fetal death,Time to event,1,1,Obstetrics,Ondansetron,Pharmacological,A04AA01,Active comparator,Comparator antiemetics,New-user design,Not reported,No,hdPS,No,Primary analysis,,,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,27,,Unclear,Logistic regression,,Yes,Adjustment,,No additional variables used with/before/after hdPS,No,Cox regression,150197,306766,Yes,No,,,Yes,Not reported,,,Not reported,Specify software,No,,,STROBE,Not reported,On demand,SAS,Assignment (ITT),HR 0.91,Serious,Low,Low,Low,NI,Low,NI,Serious
Comparison of risk of cardiovascular disease related adverse events between selective serotonin reuptake inhibitor users and serotonin  norepinephrine reuptake inhibitor users in Korean adult patients with depression: retrospective cohort study.,Done,19/1/2021,10.1016/j.psychres.2021.113744,Unclear,South Korea,Public,Not reported,,Not reported,1,Health Insurance Review and Assessment,Other,PCD,South Korea,Safety,ITT,3,Hemorrhagic stroke / ischemic stroke / myocardial infarction,Time to event,1,1,Psychiatry,SSRI,Pharmacological,N06AB,Active comparator,SRNI,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,365,"Diagnoses (all),Drugs (all)",,,,,,,,,Schneeweiss citation,Schneeweiss citation,14,500,Unclear,Schneeweiss citation,,Not reported,Adjustment,,To adjust with hdPS (stratas or not),No,Cox regression,64739,3711,Unclear,Yes,,,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,STROBE,Not reported,Not reported,SAS,Assignment (ITT),HR 1.100,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events,Done,1/9/2017,10.1183/13993003.02245-2016,Yes,Canada,"Public,Private",Not reported,,Mentioned but not available,1,CPRD + HES,CPRD (+HES),Both linked,UK,Safety,"Per-protocol,ITT",3,myocardial infarction / heart failure / stroke,Time to event,1,1,Pulmonary Medicine,combination bronchodilators,Pharmacological,R03A,Active comparator,monotherapy,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,365,"Diagnoses (all),Procedures (all),Drugs (all)",,,,,,,,,Schneeweiss citation,Schneeweiss citation,4,500,No,Logistic regression,,Not reported,Matching,,"To match with the hdPS,To adjust after hdPS matching/weighting",No,Cox regression,32741,100613,Yes,No,31138,31138,No,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.12,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Diabetes self-management education is not associated with a reduction in long-term diabetes complications: an effectiveness study in an elderly population,Done,4/3/2015,10.1111/jep.12360,Yes,Canada,Public,Not reported,,Not reported,1,ICES,Ontario health databases,PCD,Canada,Efficacy,ITT,8,hospitalization for coronary artery disease / stroke / ischaemic limb / foot ulcer cellulitis / non-traumatic lower extremity amputation / renal dialysis / proliferative retinopathy / all-cause mortality,Time to event,1,1,Diabetology,Attendee of self education,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,7,1095,"Medical encounters,Outpatient drug dispensation,Inpatient diagnoses,Outpatient diagnoses,Inpatient procedures (including tests)",emergency department diagnoses / procedures,,,,,,,,Schneeweiss citation,Schneeweiss citation,13,500,No,Logistic regression,,Not reported,Matching,,To match with the hdPS,No,Cox regression,8207,92640,Yes,No,7988,7988,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.13,Moderate,Moderate,Moderate,Low,NI,Low,NI,Moderate
Dialysis therapy and mortality in older adults with heart failure and advanced chronic kidney disease: A high-dimensional propensity-matched cohort study,Done,21/1/2022,10.1371/journal.pone.0262706,Yes,USA,Public,Not reported,,Not reported,1,Kaiser Permanente Northern California,Kaiser Permanente,Both linked,USA,Both,ITT,1,Death,Time to event,1,1,Nephrology,Dialysis initiation,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,,"Outpatient prescriptions,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient prescriptions,Inpatient diagnoses,Inpatient procedures (including tests)",,ICD-9,CPT,,,,Yes,200,Schneeweiss citation,Bross formula,,100,Unclear,Logistic regression,,Not reported,Matching,,"To match with the hdPS,To adjust after hdPS matching/weighting",No,Cox regression,412,22302,Yes,Yes,348,947,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.67,Moderate,Moderate,Low,Low,NI,Low,NI,Serious
Digoxin and Risk of Death in Adults With Atrial Fibrillation The ATRIA-CVRN Study,Done,20/11/2014,10.1161/CIRCEP.114.002292,Yes,USA,Public,Not reported,,Not reported,2,Kaiser Permanente Northern California / Kaiser Permanente Southern California,Kaiser Permanente,Both linked,USA,Both,"ITT,Per-protocol",2,Death / Hospitalization,Time to event,1,1,Cardiology,Digoxin,Pharmacological,C01AA05,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,1825,"Drugs (all),Diagnoses (all),Procedures (all)",Medication prescriptions / diagnoses / procedures,ICD-9,Not reported,Not reported,,,Yes,200,Schneeweiss citation,Schneeweiss citation,,300,No,Schneeweiss citation,,Not reported,Matching,,To match with the hdPS,No,Cox regression,4858,22430,Yes,Yes,4231,10556,No,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),mortality HR 1.71,Moderate,Serious,Low,Low,Low,Low,NI,Serious
Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes,Done,22/4/2016,10.1002/pds.4014,Yes,Canada,Public,Not reported,,Mentioned but not available,1,Alberta Health,Other canadian databases,PCD,Canada,Safety,Per-protocol,1,MACE,Time to event,2,2,Diabetology,Gliclazide low dose,Pharmacological,A10BB09,Active comparator,High dose gliclazide,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,1095,"Outpatient drug dispensation,Inpatient diagnoses,Inpatient procedures (including tests),Medical encounters",emergency diagnoses / emergency procedures,,,,,,Yes,200,Schneeweiss citation,Schneeweiss citation,28,50,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,,,Yes,Yes,2895,2895,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,Stata,Starting and adhering (PP),HR 1.15,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study,Done,4/10/2016,10.1111/1471-0528.14358,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Safety,ITT,1,venous thromboembolism,Binary,1,1,Gynecology,Drospirenone,Pharmacological,G03AC10,Active comparator,Levonorgestrel,Other,Not reported,No,hdPS,No,Primary analysis,,365,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,25,500,Unclear,Schneeweiss citation,,Not reported,Adjustment,,To adjust with hdPS (stratas or not),No,Poisson regression,38696,301047,Yes,Yes,51,366,Yes,Not reported,,PS distribution plots,Not reported,Specify total number of covariates included,No,,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),HR 0.89,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First- Time Users and Restarters,Done,5/4/2017,10.1007/s40264-017-0525-2,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD + HES,CPRD (+HES),Both linked,UK,Safety,Per-protocol,2,incident VTE / pulmonary embolism,Time to event,1,1,Gynecology,Drospirenone,Pharmacological,G03AC10,Active comparator,Levonorgestrel,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,1825,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,27,500,No,Schneeweiss citation,,Yes,Adjustment on deciles (stratification),Matching,No additional variables used with/before/after hdPS,No,Cox regression,3582,51557,No,Yes,,,Yes,Not reported,,PS distribution plots,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 3.2,Moderate,Low,Low,Moderate,Low,Moderate,NI,Moderate
Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension,Done,27/7/2018,10.1093/eurheartj/ehy420,Yes,Italy,Private,Not reported,,Not reported,1,NHS Lombardy,Other,PCD,Italy,Efficacy,Per-protocol,1,CV event,Time to event,1,1,Cardiology,Combination therapy,Pharmacological,C02,Active comparator,monotherapy,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,2,730,"Outpatient drug dispensation,Hospitalizations (all)",,Not reported,,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,11,200,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,7456,37078,Unclear,No,,,No,Not reported,,,Not reported,"Specify total number of covariates included,Specify software,Specify data dimensions",Yes,Propensity score with predefined variables,self controlled case series,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.85,Moderate,Serious,Low,Low,NI,Low,NI,Serious
Effect of Selective Serotonin Reuptake Inhibitors on Healthcare Utilization in Patients with Post- Traumatic Stress Disorder and Alcohol Use Disorder,Done,11/6/2019,10.1093/alcalc/agz045,No,USA,Public,Not reported,,Not reported,1,North Texas Veterans Healthcare System,Veterans Administration databases,PCD,USA,Efficacy,ITT,6,discharges for all-cause and alcohol-related medical hospitalization / psychiatric hospitalization / ER visits,Binary,1,1,Psychiatry,SSRI,Pharmacological,N06AB,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,365,"Diagnoses (all),Drugs (all),Procedures (all)",,ICD-9,CPT,Generic drug names,Other,4 digit ICD / 4 digit CPT,No,,"""Once, sporadic, frequent""",Bross formula,6,,No,Schneeweiss citation,,Not reported,Weighting,,To adjust after hdPS matching/weighting,No,Logistic regression,1639,1596,Unclear,No,,,No,Standardized Difference,,,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify software,Specify covariate priorisation method",No,,,Not reported,Not reported,Not reported,Other,Assignment (ITT),OR 0.939,Moderate,Moderate,Low,Low,NI,Low,NI,Moderate
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation,Done,8/11/2018,10.1111/bcp.13815,Yes,France,Private,Yes,EUPAS / CT.GOV,Available,1,SNDS,SNDS,PCD,France,Both,Per-protocol,4,hospitalizations with a main diagnosis of ischaemic stroke / systemic embolism / major bleeding / all-cause death,Time to event,2,1,Cardiology,Dabigatran 110 mg,Pharmacological,B01AE07,Active comparator,VKA,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,1095,"Outpatient drug dispensation,Inpatient diagnoses,Medical encounters,Outpatient diagnoses",LTD,ICD-10,,,,,,,Schneeweiss citation,Association with outcome,24,500,No,Logistic regression,,Not reported,Matching,Adjustment on deciles (stratification),No additional variables used with/before/after hdPS,Unclear,Cox regression,15532,44653,Yes,Yes,14442,14442,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.69,Moderate,Low,Low,Serious,NI,Low,Moderate,Serious
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation A Population-Based New Users High-Dimensional Propensity Score  Matched Cohorts Study,Done,14/6/2019,10.1161/STROKEAHA.119.025824,Yes,France,Private,Yes,EUPAS,Available,1,SNDS,SNDS,PCD,France,Both,Per-protocol,3,hospitalization for ischemic stroke or systemic embolism / hospitalization for major bleeding / all-cause death,Time to event,2,1,Cardiology,Rivaroxaban  15,Pharmacological,B01AF01,Active comparator,VKA,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,1095,"Outpatient drug dispensation,Inpatient diagnoses,Medical encounters,Outpatient diagnoses",LTD,ICD-10,Not reported,ATC,"3 digit ICD,Other",ATC7,,,"""Once, sporadic, frequent""",Association with outcome,17,500,No,Logistic regression,,Not reported,Matching,Adjustment on deciles (stratification),No additional variables used with/before/after hdPS,Yes,Fine-Gray,24529,108656,Yes,Yes,23314,23314,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.80,Moderate,Low,Low,Serious,NI,Low,Moderate,Serious
"Effectiveness of Prophylactic Use of Hepatoprotectants for Tuberculosis Drug-Induced Liver Injury: A Population-Based Cohort Analysis Involving 6,743 Chinese Patients",Done,20/4/2022,10.3389/fphar.2022.813682,Unclear,China,Public,Not reported,,Not reported,1,Ningbo Regional Health Database + Ningbo Community CDC TB registry,Other,Both linked,China,Efficacy,ITT,1,Drug-Induced Liver Injury,Time to event,1,1,Infectious Disease Medicine,hepatoprotectors,Pharmacological,A05BA,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,365,"Outpatient drug dispensation,Inpatient drug dispensation,Inpatient diagnoses,Outpatient diagnoses",,ICD-10,,Not reported,,,Yes,500,"""Once, sporadic, frequent""",Schneeweiss citation,11,200,No,Schneeweiss citation,,Yes,Weighting,,,No,Cox regression,2886,3857,Yes,No,,,Yes,Standardized Difference,,,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,"SAS,R",Assignment (ITT),HR 1.35,Moderate,Low,Low,Low,Low,Low,NI,Moderate
Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study,Done,21/7/2021,10.1038/s41386-021-01117-z,Yes,USA,Public,Not reported,,Not reported,1,Kaiser Permanente Northern California,Kaiser Permanente,Both linked,USA,Efficacy,Per-protocol,1,change in alcoholic drinks consumed per week,Discrete,1,1,Nephrology,Spironolactone,Pharmacological,C03DA01,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient diagnoses,Inpatient diagnoses,Procedures (all),Outpatient drug dispensation,Medical encounters",,ICD-10,,Generic drug names,,,Yes,300,Schneeweiss citation,Association with exposure,10,100,No,Logistic regression,,Not reported,Matching,,To adjust after hdPS matching/weighting,No,Other,527,58607,Yes,Yes,523,523,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),DiD -0.76,Moderate,Serious,Low,Moderate,NI,Serious,NI,Serious
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example,Done,19/11/2013,10.1186/1471-2288-13-142,Yes,USA,"Public,Private",Not reported,,Not reported,1,Truven MarketScan,Truven Marketscan,PCD,USA,Safety,ITT,1,Upper gastrointestinal complications,Time to event,1,1,Rheumatology,celecoxib,Pharmacological,L01XX33,Active comparator,NSAIDs,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests)",,ICD-9,"CPT,HCPCS","Generic drug names,ATC",Other,Varying tests of granularity,Yes,200,"""Once, sporadic, frequent""",Bross formula,11,500,No,Schneeweiss citation,,Not reported,Adjustment on deciles (stratification),,To adjust with hdPS (stratas or not),No,Logistic regression,7197,11632,No,No,7197,11632,Yes,Not reported,Different granularity,,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),HR 0.92,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Estimation of high‐dimensional propensity scores with multiple exposure levels,Done,11/8/2019,10.1002/pds.4890,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD + HES,CPRD (+HES),Both linked,UK,Efficacy,Per-protocol,1,Composite of cardiovascular event,Time to event,2,2,Addiction Medicine,varenicline,Pharmacological,N07BA03,Active comparator,Bupropion,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient prescriptions,Outpatient procedures (including tests),Outpatient diagnoses,Other,Administrative data",demographic characteristics / general practitioner practice characteristics,Not reported,Not reported,Not reported,,,Yes,500,Schneeweiss citation,Schneeweiss citation,28,500,No,Logistic regression,,Yes,Adjustment on deciles (stratification),,To adjust with hdPS (stratas or not),No,Cox regression,68468,9931,Unclear,Yes,68468,9931,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,Not reported,Starting and adhering (PP),HR 1,Moderate,Low,Low,Serious,Low,Low,NI,Serious
Examining the risk of depression or self- harm associated with incretin-based  therapies used to manage  hyperglycaemia in patients with type 2  diabetes: a cohort study using the UK  Clinical Practice Research Datalink,Done,31/12/2018,10.1136/bmjopen-2018-023830,Unclear,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Safety,Per-protocol,1,composite of new depression or self-harm,Time to event,2,1,Diabetology,DPP4i,Pharmacological,A10BH,Active comparator,sulfonylureas,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,365,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,19,40,No,Logistic regression,,Yes,Adjustment on deciles (stratification),Matching,To adjust with hdPS (stratas or not),No,Cox regression,6214,22653,Yes,Yes,6206,22128,Yes,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,R,Starting and adhering (PP),HR 1.26,Serious,Low,Low,Serious,NI,Low,NI,Serious
Eye drops for dry eye disease during pregnancy and adverse neonatal outcomes: high-dimensional propensity score analyses,Done,29/8/2021,10.1080/09286586.2021.1971263,Yes,Japan,Public,Not reported,,Not reported,1,JMDC Claims Database,Other,PCD,Japan,Safety,ITT,,congenital anomalies / preterm birth / low birthweight/ composite,Discrete,3,1,Ophtalmology,hyaluronate 0.1%,Pharmacological,S01KA01,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Secondary analysis,4,180,"Outpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests),Inpatient diagnoses",,ICD-10,Not reported,ATC,,,Yes,500,Schneeweiss citation,Schneeweiss citation,20,500,Yes,Logistic regression,,No,Adjustment,,No additional variables used with/before/after hdPS,No,Poisson regression,544,3872,No,Yes,544,3872,No,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included",Yes,Propensity score with predefined variables,,Not reported,No,No,Not reported,Assignment (ITT),RD 0.4,Serious,Serious,Low,Serious,NI,Low,NI,Serious
"Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study",Done,11/6/2018,10.1371/journal.pmed.1002584,Yes,Canada,Public,Not reported,,Not reported,1,ICES,Ontario health databases,PCD,Canada,Both,"Per-protocol,ITT",1,"composite of all-cause death and hospitalization for acute myocardial infarction, heart failure or stroke",Time to event,1,1,Cardiology,multipill hypertensive,Pharmacological,C02,Active comparator,fixed dose combination,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,7,365,"Outpatient drug dispensation,Outpatient diagnoses,Medical encounters,Inpatient diagnoses,Inpatient procedures (including tests)",emergency diagnoses / emergency procedures,,,,,,Yes,200,Schneeweiss citation,Schneeweiss citation,7,500,No,Logistic regression,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,23976,7532,Yes,Yes,6675,6675,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",Yes,Negative controls,,"RECORD,STROBE",Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.06,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study,Done,23/10/2019,10.1016/j.cmi.2019.10.016,Yes,Canada,Public,Not reported,,Mentioned but not available,6,CNODES,CNODES network databases,PCD,Canada,Efficacy,ITT,1,repeat outpatient visits for UTI / emergency department visits for UTI / hospitalizations for UTI / repeat antibiotic dispensation,Time to event,1,1,Infectious Disease Medicine,fluoroquinolone,Pharmacological,J01MA,Active comparator,non- fluoroquinolone,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient diagnoses,Medical encounters,Outpatient drug dispensation,Inpatient diagnoses,Inpatient procedures (including tests)",,"ICD-10,ICD-9",,,,,,,Schneeweiss citation,Bross formula,2,500,No,Logistic regression,,Not reported,Weighting,,,No,Logistic regression,,,,,,,No,Not reported,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included",No,,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),OR 0.85,Moderate,Low,Low,Low,NI,Moderate,NI,Moderate
Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics,Done,12/11/2016,10.1016/j.ijcard.2016.11.245,Yes,USA,Public,Not reported,,Not reported,1,Medicaid,Medicaid or Medicare,PCD,USA,Safety,Per-protocol,1,composite of GIB or ICH,Time to event,7,1,Cardiology,Atorvastatin + warfarin,Pharmacological,C10AA05,Active comparator,Pravastatin + warfarin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,9,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient procedures (including tests)",other settings diagnoses / procedures,ICD-9,"CPT,HCPCS",Generic drug names,"3 digit ICD,5 digit CPT,Other",,Yes,200,None,Bross formula,24,654,No,Logistic regression,,Not reported,Adjustment,,No additional variables used with/before/after hdPS,Yes,Cox regression,79391,20238,Unclear,No,,,Yes,Not reported,,,Yes,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.99,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
High-dimensional propensity scores improved the control of indication bias in surgical comparative effectiveness studies,Done,14/10/2020,10.1016/j.jclinepi.2020.10.003,Yes,France,Public,Not reported,,Not reported,1,PMSI,Other,PCD,France,Both,ITT,1,death,Time to event,1,1,General Surgery,TAVI,Not-pharmacological,,Active comparator,SAVR,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,2,365,"Inpatient diagnoses,Inpatient procedures (including tests)",,ICD-10,CCAM,,,,,,"""Once, sporadic, frequent""",Bross formula,44,300,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Logistic regression,29995,29063,Yes,Yes,7157,7157,No,Standardized Difference,Different total number of covariates,,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.53,Moderate,Low,Low,Low,NI,Low,NI,Moderate
High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications,Done,6/6/2012,10.1007/s00228-012-1334-2,Yes,Germany,Public,Not reported,,Not reported,1,GePARD,GePaRD,PCD,Germany,Safety,Per-protocol,1,upper gastrointestinal complications,Discrete,1,1,Rheumatology,Coxib,Pharmacological,M01AH,Active comparator,tNSAID,New-user design,Not reported,Not reported,hdPS,No,Sensitivity analysis,6,180,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests),Disease specific",Outpatient surgery codes,ICD-10,Other,ATC,"3 digit ICD,Other","4 digit OPS, 5 digit EBM, full ATC",,,Schneeweiss citation,Bross formula,4,200,No,Logistic regression,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Poisson regression,37281,2104614,Yes,Yes,37281,37281,Yes,Not reported,Different total number of covariates,Sequential addition of variables plots,Not reported,"Specify data dimensions,Description parameters for feature generation,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),UGIC RR 0.68,Moderate,Low,Low,Serious,NI,Low,NI,Serious
"Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases",Done,29/5/2014,10.1136/bmj.g3244,Yes,Canada,Public,Not reported,,Mentioned but not available,8,Alberta / Manitoba / Nova Scotia / Ontario / Quebec / Saskatchewan / CPRD / MarketScan,"CNODES network databases,Truven Marketscan,CPRD (+HES)","PCD,EMR / Registry",Canada / UK / USA,Safety,Per-protocol,1,first occurrence of a hospitalisation with a principal or secondary diagnosis for diabetes,Binary,1,1,Cardiology,Higher potency statins,Pharmacological,C10AA,Active comparator,Lower potency statins,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,9,500,No,Logistic regression,,Yes,Adjustment on deciles (stratification),,"To match before the hdPS,To adjust after hdPS matching/weighting",No,Logistic regression,89077,47889,Yes,No,30843,30843,No,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),RR 1.15,Moderate,Low,Low,Moderate,NI,Moderate,NI,Moderate
Hospitalization for Hemorrhage Among Warfarin Recipients Prescribed Amiodarone,Done,1/8/2013,10.1016/j.amjcard.2013.03.051,Yes,Canada,Public,Not reported,,Not reported,1,ODB + DAD + OHIP + RPDB,Ontario health databases,PCD,Canada,Safety,ITT,1,Hospitalization for hemorrhage within 30 days,Time to event,1,1,Cardiology,Amiodarone,Pharmacological,C01BD01,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests)",,"ICD-10,ICD-9",Not reported,Not reported,,,Yes,200,Schneeweiss citation,Bross formula,7,500,No,Logistic regression,,Not reported,Matching,,To match with the hdPS,No,Cox regression,11665,48832,Yes,No,7124,7124,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),Hemorrhage 2.45,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism,Done,22/8/2018,10.1111/jth.14303,Yes,USA,Public,Not reported,,Mentioned but not available,1,MarketScan + Medicare,Medicaid or Medicare,PCD,USA,Safety,ITT,1,hospitalized bleeding events,Time to event,3,2,Cardiology,LMWH,Pharmacological,B01AB,Active comparator,warfarin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,90,Outpatient drug dispensation,,,,,,,Yes,200,Schneeweiss citation,Schneeweiss citation,3,500,No,Schneeweiss citation,,Not reported,Adjustment,,,No,Cox regression,8803,14833,Unclear,No,,,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.97,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study,Done,24/4/2014,10.1136/bmj.g2780,Yes,Canada,Public,Not reported,,Not reported,1,CPRD + HES,CPRD (+HES),Both linked,UK,Safety,"ITT,Per-protocol",1,acute pancreatitis,Time to event,1,1,Diabetology,Incretin based drugs,Pharmacological,A10BH / A10BJ,Active comparator,Sulfonylureas,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient prescriptions,Procedures (all),Diagnoses (all),Administrative data",procedures / diagnoses / disease history / administrative information,"Read Codes,ICD-10",Other,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,13,500,No,Logistic regression,,Yes,Adjustment on deciles (stratification),Matching,To adjust with hdPS (stratas or not),No,Cox regression,20951,52656,No,Yes,20748,51712,Yes,C-statistic,,PS distribution plots,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.00,Moderate,Low,Low,Serious,Moderate,Low,Serious,Serious
Infant Respiratory Outcomes Associated with Prenatal Exposure to Maternal 2009 A/H1N1 Influenza Vaccination,Done,3/8/2016,10.1371/journal.pone.0160342,Yes,Canada,Public,Not reported,,Not reported,1,ICES,Ontario health databases,PCD,Canada,Safety,ITT,1,infant influenza,Discrete,1,1,Infectious Disease Medicine,2009 A/H1N1 vaccination,Pharmacological,J07BB02,Standard care,Unexposed,New-user design,Not reported,No,hdPS,No,Primary analysis,,,Unclear,,,,,,,,,Not reported,Not reported,13,500,No,Not reported,,Not reported,Adjustment on deciles (stratification),,,No,Poisson regression,36033,81302,Unclear,No,,,Yes,Standardized Difference,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),IRR 1.05,Moderate,Low,Low,Low,Moderate,Moderate,NI,Moderate
"Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study",Done,11/9/2020,10.1053/ j.ajkd.2020.07.018,Unclear,Canada,Public,Not reported,,Not reported,1,ICES,Ontario health databases,PCD,Canada,Both,"ITT,Per-protocol",8,eGFR decline / kidney replacement therapy / cardiac events / all-cause mortality / hypotension / syncope / falls / fractures,Time to event,1,1,Cardiology,alphablocker,Pharmacological,C02CA,Active comparator,non AB blood pressure lowering medication,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Emergency visits (all),Inpatient procedures (including tests),Inpatient diagnoses",,ICD-10,Other,Generic drug names,"3 digit ICD,Generic drug name",,Yes,200,"""Once, sporadic, frequent""",Bross formula,6,201,No,Logistic regression,,Not reported,Matching,,To match with the hdPS,Yes,Fine-Gray,16511,364609,Yes,Yes,16088,16088,No,Standardized Difference,,,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Negative controls,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.14,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Long-Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events,Done,1/1/2017,10.1016/j.chest.2016.08.001,Yes,Canada,"Public,Private",Not reported,,Mentioned but not available,1,CPRD + HES,CPRD (+HES),Both linked,UK,Safety,"Per-protocol,ITT",5,myocardial infarction / heart failure / stroke / arrhythmia / pneumonia,Time to event,1,1,Pulmonary Medicine,Tiotropium,Pharmacological,R03BB04,Active comparator,LABA,New-user design,Not reported,No,hdPS,No,Primary analysis,5,365,"Procedures (all),Diagnoses (all),Drugs (all),Symptoms",signs / symptoms,,,,,,,,Schneeweiss citation,Schneeweiss citation,7,500,No,Logistic regression,,Not reported,Matching,,To adjust after hdPS matching/weighting,No,Cox regression,26442,88955,Yes,Yes,26442,26442,No,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.10,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease,Done,5/2/2018,10.1001/jamainternmed.2017.8462,Yes,USA,Public,Not reported,,Not reported,1,Kaiser Permanente,Kaiser Permanente,Both linked,USA,Both,ITT,3,all-cause mortality / heart failure hospitalizations / any-cause hospitalizations,Time to event,1,1,Cardiology,ICD,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,,"Hospitalizations (all),Procedures (all),Diagnoses (all),Drugs (all),Lab records (all),Medical encounters,Other,Administrative data",admin,,,,,,Yes,200,"""Once, sporadic, frequent""",Bross formula,,500,No,Logistic regression,,Not reported,Matching,,"To match with the hdPS,To adjust after hdPS matching/weighting",No,Cox regression,3312,15545,Yes,Yes,1556,4321,No,Standardized Difference,,,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.09,Moderate,Moderate,Low,Low,NI,Low,NI,Moderate
Metformin versus sulphonylureas for new onset atrial fibrillation  and stroke in type 2 diabetes mellitus: a population‑based study,Done,3/2/2022,10.1007/s00592-021-01841-4,Yes,UK,Public,Not reported,,Not reported,1,Clinical Data Analysis and Reporting System (CDARS),Other,Hospital database,Hong Kong,Safety,Unclear,4,new-onset AF / new-onset stroke / cardiovascular mortality / all-cause mortality,Time to event,1,1,Diabetology,Sulphonylurea,Pharmacological,A10BB,Active comparator,Metformin,Other,Not reported,Not reported,hdPS,No,Secondary analysis,,,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,,,,Schneeweiss citation,,,Matching,,,,Cox regression,,,Unclear,Yes,,,Yes,Not reported,,,,Specify software,Yes,"Multivariable analysis on predefined variables,Propensity score with predefined variables",,Not reported,Not reported,On demand,R,Assignment (ITT),HR 3.56,Serious,Serious,Serious,Low,NI,Low,NI,Serious
Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel,Done,8/2/2014,10.1007/s40264-014-0136-0,Yes,USA,"Private,Public",Not reported,,Not reported,1,HealthCore Integrated Research Database,Other US commercial,PCD,USA,Both,Per-protocol,5,MI hospitalization / hospitalization for ischemic stroke / hospitalization for hemorrhagic stroke / hospitalization for severe upper gastrointestinal bleed / death from any cause,Time to event,1,1,Cardiology,Prasugrel,Pharmacological,B01AC22,Active comparator,clopidogrel,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,,"Drugs (all),Procedures (all),Diagnoses (all)",drug / procedure / diagnosis,ICD-9,CPT,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,27,,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Poisson regression,1282,8263,Yes,Yes,1255,1255,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),Rate difference -22.42,Moderate,Low,Low,Serious,NI,Low,Serious,Serious
Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study,Done,14/3/2018,10.1371/journal.pone.0193800,Yes,USA,Public,Not reported,,Not reported,1,Medicaid,Medicaid or Medicare,PCD,USA,Safety,Per-protocol,3,all-cause mortality / composite AMI-ischemic stroke / composite GIB/ICH,Time to event,9,1,Rheumatology,celecoxib,Pharmacological,L01XX33,Active comparator,ibuprofen,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,9,365,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests),Other",other settings,ICD-9,"CPT,HCPCS",Generic drug names,"3 digit ICD,5 digit CPT,Generic drug name",,Yes,200,None,Bross formula,135,596,No,Logistic regression,,Not reported,Adjustment,,To adjust with hdPS (stratas or not),Yes,Cox regression,69779,66317,No,Yes,,,Yes,Standardized Difference,,Inspection of selected variables,Yes,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.28,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients,Done,3/12/2018,10.1080/03007995.2018.1541445,Yes,USA,Public,Not reported,,Not reported,1,MarketScan + Medicare,Truven Marketscan,PCD,USA,Efficacy,ITT,1,VTE,Time to event,7,1,Cardiology,DOAC,Pharmacological,B01AF,Active comparator,VKA,New-user design,Not reported,No,hdPS,No,Primary analysis,5,,"Inpatient diagnoses,Outpatient diagnoses,Outpatient drug dispensation,Outpatient procedures (including tests),Inpatient procedures (including tests)",,Not reported,Not reported,Not reported,,,Yes,200,Schneeweiss citation,Bross formula,35,500,No,Logistic regression,,Not reported,Matching,,To match with the hdPS,No,Cox regression,28089,41592,Yes,No,27065,27065,No,Not reported,,,Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,On demand,SAS,Assignment (ITT),HR 0.55,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Outcomes Associated With Early Preventive Dental Care Among Medicaid-Enrolled Children in Alabama,Done,27/2/2017,10.1001/jamapediatrics.2016.4514,No,USA,Public,Not reported,,Not reported,1,Alabama Medicaid,Medicaid or Medicare,PCD,USA,Efficacy,ITT,1,annual caries-related visits,Binary,1,1,Odontology,Received Preventive Care,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,730,"Outpatient diagnoses,Outpatient drug dispensation,Inpatient diagnoses,Outpatient procedures (including tests)",,ICD-9,Not reported,Other,,,,,Schneeweiss citation,Schneeweiss citation,3,500,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Logistic regression,,,Unclear,No,,,No,Standardized Difference,,Inspection of selected variables,Yes,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),Beta 0.71,Moderate,Moderate,Serious,Low,NI,Serious,NI,Serious
Performance of the High-dimensional Propensity Score in a Nordic Healthcare Model,Done,9/2/2017,10.1111/bcpt.12716,Yes,Denmark,Not reported,Not reported,,Not reported,1,Danish National Prescription Register + Patient Register + Civil registration,Other,EMR / Registry,Denmark,Safety,ITT,1,upper gastrointestinal bleeding,Time to event,1,1,Rheumatology,Coxib,Pharmacological,M01AH,Active comparator,tNSAID,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,2,180,"Diagnoses (all),Drugs (all)",Diagnoses / Drugs,ICD-10,,ATC,Other,4-digit ICD / full ATC,Yes,500,Schneeweiss citation,Association with outcome,11,500,No,Logistic regression,,Yes,Adjustment,,No additional variables used with/before/after hdPS,No,Cox regression,110285,575980,Yes,No,,,Yes,Not reported,"Different total number of covariates,Different prioritization",Inspection of selected variables,Not reported,"Specify data dimensions,Description parameters for feature generation,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software,Specify covariate priorisation method",Yes,Multivariable analysis on predefined variables,,Not reported,Not reported,Not reported,Stata,Assignment (ITT),HR 0.96,Moderate,Low,Low,Low,NI,NI,Low,Moderate
Prenatal antibiotic exposure and risk of attention-deficit/hyperactivity disorder: a population-based cohort study,Done,19/5/2020,10.1503/cmaj.190883,Unclear,Canada,Public,Not reported,,Not reported,1,Manitoba Centre for Health Policy,Other canadian databases,EMR / Registry,Canada,Safety,ITT,1,Diagnosis of ADHD,Time to event,1,1,Obstetrics,Antibiotic exposure during pregnancy,Pharmacological,J01,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests)",,"ICD-10,ICD-9",Not reported,ATC,,,Yes,200,"""Once, sporadic, frequent""",Schneeweiss citation,8,500,No,Schneeweiss citation,,Not reported,Matching,,To adjust after hdPS matching/weighting,No,Cox regression,117051,70554,Yes,Yes,64837,64837,Yes,Standardized Difference,,,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Specify total number of covariates included,Specify software",Yes,Negative controls,,Not reported,,,SAS,Assignment (ITT),GR 1.20,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Prenatal antidepressant exposure and child development at kindergarten age: a population-based study,Done,9/12/2020,10.1038/s41390-020-01269-6,Yes,Canada,Public,Not reported,,Not reported,1,MSP + DAD + BC PharmaNet + Perinatal Registry + Humain Early Learning Partnership Data,British Columbia health databases,Both linked,Canada,Safety,ITT,16,EDI subscale Readiness,Binary,1,1,Psychiatry,Prenatal antidepressant exposure,Pharmacological,N06A,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,3,365,"Outpatient diagnoses,Inpatient procedures (including tests),Inpatient diagnoses,Medical encounters,Outpatient drug dispensation",,"ICD-10,ICD-9",Other,Generic drug names,Other,Multiple ICD granularity,,,"""Once, sporadic, frequent""",Schneeweiss citation,11,500,Yes,Schneeweiss citation,,Not reported,Matching,,To adjust after hdPS matching/weighting,Yes,Logistic regression,3661,91051,Yes,Yes,2253,5609,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Description parameters for feature generation,Specify software,Describe feature recurrence assessment method",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.13,Serious,Low,Low,Low,NI,Low,NI,Serious
Prenatal Opioid Analgesics and the Risk of Adverse  Birth Outcomes,Done,3/5/2021,10.1097/EDE.0000000000001328,Yes,Canada,Public,Not reported,,Not reported,1,ICES,Ontario health databases,PCD,Canada,Safety,ITT,4,Preterm birth / SGA birth / Stillbirth / NAS,Binary,1,1,Pain medicine,Prenatal Opioid Analgesics,Pharmacological,N02A,Standard care,Unexposed,Prevalent user,Not reported,Not reported,hdPS,No,Primary analysis,4,365,"Outpatient drug dispensation,Medical encounters,Emergency visits (all),Inpatient diagnoses",,"ICD-9,ICD-10",,,,,,,Schneeweiss citation,Schneeweiss citation,19,,No,Schneeweiss citation,,Not reported,Weighting,,No additional variables used with/before/after hdPS,No,Other,25755,601417,Unclear,No,,,Yes,Not reported,,,Not reported,Specify data dimensions,Yes,Propensity score with predefined variables,,Not reported,Not reported,On demand,Not reported,Assignment (ITT),RR 1.3,Serious,Low,Low,Low,NI,Low,NI,Serious
Preventive Dental Care and Long-Term Dental Outcomes among ALL Kids Enrollees,Done,29/2/2016,10.1111/1475-6773.1 2469,Yes,USA,Public,Not reported,,Not reported,1,Alabama CHIP program,Other,EMR / Registry,USA,Efficacy,ITT,1,nonpreventive dental visits,Time to event,1,1,Odontology,preventive dental visit,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,,"Outpatient diagnoses,Inpatient diagnoses,Outpatient procedures (including tests),Outpatient drug dispensation",,Not reported,CPT,Other,,,,,Schneeweiss citation,Schneeweiss citation,15,200,Unclear,Schneeweiss citation,,Not reported,Weighting,,,No,Logistic regression,2693,2081,Unclear,No,,,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Specify total number of covariates included",No,,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),beta 0.72,Moderate,Moderate,Low,Low,Low,Serious,NI,Serious
Proton pump inhibitor use and risk of depression and  anxiety in children: nationwide cohort study,Done,22/9/2021,10.1111/cts.13225,Yes,Sweden,Public,Not reported,,Not reported,1,National Patient Register + Prescribed Drug Register + Total Population Register + Statistics Sweden,Other,EMR / Registry,Sweden,Safety,"ITT,Per-protocol",1,incident depression and anxiety,Time to event,1,1,Gastroenterology,PPI,Pharmacological,A02BC,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Sensitivity analysis,,,,,,,,,,,,Not reported,Not reported,,200,,Not reported,,,Matching,,,Yes,Cox regression,29648,687323,Yes,Yes,26556,26556,No,Not reported,,,,"Specify total number of covariates included,Specify software",Yes,"Propensity score with predefined variables,Negative controls",,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 2.31,Moderate,Low,Low,Low,Low,Low,NI,Moderate
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis,Done,16/7/2013,10.1136/gutjnl-2013-304738,Yes,Canada,Public,Not reported,,Mentioned but not available,8,Alberta / Saskatchewan / Manitoba / Ontario / Quebec / Nova Scotia / MarketScan / CPRD,"CNODES network databases,CPRD (+HES),Truven Marketscan","PCD,EMR / Registry",Canada / USA / UK,Safety,Per-protocol,1,incident HCAP,Time to event,1,2,Gastroenterology,PPI exposed,Pharmacological,A02BC,Active comparator,H2RA,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,17,500,Unclear,Logistic regression,,Not reported,Adjustment on deciles (stratification),,To adjust after hdPS matching/weighting,No,Logistic regression,,,Unclear,No,,,No,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.93,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Real-world effectiveness of early  intervention with fixed-dose tiotropium/ olodaterol vs tiotropium in Japanese patients  with COPD: a high-dimensional propensity  score–matched cohort analysis,Done,17/6/2021,10.1186/s12931-021-01776-y,No,Japan,Private,Not reported,,Mentioned but not available,1,Medical Data Vision,Other,PCD,Japan,Efficacy,"ITT,Per-protocol",1,time to escalation to LAMA/LABA/ICS triple therapy,Time to event,1,1,Pulmonary Medicine,Tiotropium + olodaterol,Pharmacological,R03BB04,Active comparator,Tiotropium,New-user design,Not reported,Yes,hdPS,No,Primary analysis,,180,,,ICD-10,Other,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,24,,Unclear,Logistic regression,,Not reported,Matching,,,No,Cox regression,1436,5352,Yes,Yes,1302,1302,No,Not reported,,,Not reported,Specify software,No,,,Not reported,On demand,On demand,Aetion,Starting and adhering (PP),HR 0.89,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study,Done,1/10/2019,10.1093/europace/euz285,Yes,France,Private,Yes,EUPAS / CT.GOV,Available,1,SNDS,SNDS,PCD,France,Both,Per-protocol,5,ischaemic stroke or systemic embolism / major bleeding / intracranial and gastrointestinal bleeding / acute coronary syndrome / all-cause death,,2,1,Cardiology,Rivaroxaban,Pharmacological,B01AF01,Active comparator,VKA,New-user design,Not reported,No,hdPS,No,Primary analysis,4,1095,"Outpatient drug dispensation,Medical encounters,Lab records (all),Diagnoses (all)",,Not reported,Not reported,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,26,500,Yes,Logistic regression,,Not reported,Matching,Adjustment,,No,Cox regression,8099,36440,Yes,No,5925,5925,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.14,Moderate,Moderate,Low,Serious,NI,Low,Moderate,Serious
Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based  cohort study,Done,14/12/2021,10.1136/bmjdrc-2021-002496,Yes,Canada,Public,Not reported,,Mentioned but not available,2,Province of Alberta / CPRD,"CPRD (+HES),Other canadian databases","PCD,EMR / Registry",Canada / UK,Both,"Per-protocol,ITT",1,"new or worsening nephropathy,",Time to event,1,1,Diabetology,SLGT2i,Pharmacological,A10BK,Active comparator,DPP4i,New-user design,Not reported,No,hdPS,No,Primary analysis,6,365,"Hospitalizations (all),Emergency visits (all),Procedures (all),Diagnoses (all),Lab records (all),Drugs (all)",,"ICD-10,Read Codes",,,,,Yes,200,"""Once, sporadic, frequent""",Schneeweiss citation,30,500,Unclear,Logistic regression,,No,Matching,,,No,Cox regression,7709,12855,Yes,Yes,7470,7470,No,Not reported,,,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Specify total number of covariates included",No,,,Not reported,Not reported,No,Not reported,Starting and adhering (PP),HR 0.75,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study,Done,29/6/2018,10.1111/dom.13459,Yes,USA,Not reported,Not reported,,Not reported,1,MarketScan,Truven Marketscan,PCD,USA,Safety,Per-protocol,1,any amputation,Time to event,1,1,Diabetology,SGLT2i,Pharmacological,A10BK,Active comparator,DPP4i,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests),Outpatient diagnoses",,,,,,,,,Schneeweiss citation,Schneeweiss citation,500,8,Unclear,Schneeweiss citation,,Not reported,Matching,"Stratification,Adjustment",No additional variables used with/before/after hdPS,No,Cox regression,34999,102013,Yes,Yes,30216,30216,No,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis",No,,,Not reported,Not reported,Not reported,Not reported,Starting and adhering (PP),HR 1.38,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants,Done,22/4/2020,10.1053/j.ajkd.2020.02.446,Yes,Canada,Public,Not reported,,Mentioned but not available,1,ICES,Ontario health databases,PCD,Canada,Both,Per-protocol,1,Composite of CV events,Time to event,1,1,Cardiology,"DOAC (apixaban, dabi, rivaro)",Pharmacological,B01AF,Active comparator,VKA,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Emergency visits (all),Other",,ICD-10,Other,ATC,"3 digit ICD,Other",full ATC,,,Schneeweiss citation,Bross formula,,500,Unclear,Schneeweiss citation,,Not reported,Matching,,To adjust after hdPS matching/weighting,Yes,Cox regression,65335,136204,Yes,Yes,27552,27552,No,Standardized Difference,,Inspection of selected variables,Not reported,"Specify data dimensions,Description parameters for feature generation,Specify covariate priorisation method,Specify total number of covariates included,Specify software",No,,,RECORD,Not reported,Not reported,SAS,Assignment (ITT),HR 0.82,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Risk of congenital anomalies in infants born to women  with autoimmune disease using biologics before or during  pregnancy: a population-based cohort study,Done,18/3/2019,PMID: 30943142,Yes,Canada,Public,Not reported,,Not reported,1,Population Data BC,British Columbia health databases,PCD,Canada,Safety,ITT,1,congenital  anomalies,Binary,1,1,Rheumatology,Biologic exposed,Pharmacological,L04,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Other",,Not reported,,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,31,50,Yes,Schneeweiss citation,,Not reported,Matching,Adjustment,,No,Logistic regression,180,8457,Yes,No,180,581,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),OR 1.06,Moderate,Serious,Low,Low,NI,Low,NI,Serious
"Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study",Done,1/10/2021,10.2147/COPD.S323391,Yes,Taiwan,Public,Not reported,,Mentioned but not available,1,National Health Insurance,Other,PCD,Taiwan,Efficacy,"ITT,Per-protocol",1,COPD exacerbations,Time to event,1,1,Cardiology,Statins,Pharmacological,C10AA,Active comparator,fibrates,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,365,Unclear,,ICD-9,,ATC,,,,,Schneeweiss citation,Schneeweiss citation,78,100,No,Schneeweiss citation,,Not reported,Matching,,,No,Cox regression,110726,24183,Yes,Yes,24120,24120,No,Standardized Difference,,,Not reported,Specify total number of covariates included,Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),HR 1.05,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Risk of death among users of Proton  Pump Inhibitors: a longitudinal  observational cohort study of United  States veterans,Done,22/3/2017,10.1136/bmjopen-2016-015735,No,USA,Public,Not reported,,Not reported,1,Department of Veterans Affairs databases,Veterans Administration databases,PCD,USA,Safety,Per-protocol,1,time to death,Time to event,1,1,Gastroenterology,PPI,Pharmacological,A02BC,Active comparator,H2 blockers,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient procedures (including tests)",,ICD-9,CPT,Generic drug names,"3 digit ICD,Generic drug name,Other",,Yes,300,"""Once, sporadic, frequent""",Bross formula,4,500,No,Logistic regression,,Not reported,Adjustment on deciles (stratification),,,No,Cox regression,275977,73335,No,No,275977,73335,Yes,Not reported,,,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify total number of covariates included,Specify software,Specify covariate priorisation method",Yes,"Propensity score with predefined variables,Negative controls",,Not reported,Not reported,On demand,SAS,Starting and adhering (PP),HR 1.16,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Risk of Diabetes Hospitalization or Diabetes Drug Intensication in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies,Done,10/5/2018,10.4088/PCC.17m02220,No,USA,Public,Not reported,,Not reported,1,MarketScan,Truven Marketscan,PCD,USA,Safety,Per-protocol,1,time to first diabetes related hospitalization or treatment intensification,Time to event,1,1,Psychiatry,Second-Generation Antipsychotics,Pharmacological,N05A,Active comparator,non SGA,New-user design,Not reported,Yes,hdPS,No,Primary analysis,6,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests),Medical encounters",,,,,,,,,Schneeweiss citation,Schneeweiss citation,19,500,Unclear,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,6625,23921,Yes,No,6465,6465,No,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.03,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age,Done,10/6/2019,10.1001/jamainternmed.2019.0631,Yes,Canada,Public,Not reported,,Not reported,1,ICES,Ontario health databases,PCD,Canada,Safety,ITT,1,hospitalization or emergency department visit for a composite of adverse GI events,Time to event,1,1,Nephrology,sodium polystyrene sulfonate,Pharmacological,V03AE01,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,7,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient procedures (including tests),Medical encounters",,ICD-10,Other,Generic drug names,"3 digit ICD,Generic drug name",,No,,"""Once, sporadic, frequent""",Bross formula,,200,,Schneeweiss citation,,Not reported,Matching,,To match with the hdPS,Yes,Cox regression,27704,1826162,Yes,Yes,20020,20020,Yes,Standardized Difference,,Inspection of selected variables,Yes,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Negative controls,,RECORD,Not reported,Not reported,SAS,Assignment (ITT),HR 1.94,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Risk of Ischemic Cerebrovascular and Coronary Events in Adult Users of Anticonvulsant Medications in Routine Care Settings,Done,24/6/2013,10.1161/JAHA.113.000208,Yes,USA,Private,Not reported,,Not reported,1,HealthCore Integrated Research Database,Other US commercial,PCD,USA,Safety,"Per-protocol,ITT",1,Composite of ischemic coronary events and cerebrovascular events,Discrete,1,1,Neurology,Highly Inducing ACs,Pharmacological,N03A,Active comparator,Other ACs,New-user design,Not reported,Not reported,hdPS,No,Secondary analysis,5,180,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests)",,ICD-9,CPT,Generic drug names,"Generic drug name,Other",,,,"""Once, sporadic, frequent""",Schneeweiss citation,42,500,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,Yes,Poisson regression,12580,153451,Yes,No,11432,11432,No,Standardized Difference,,,Not reported,"Specify data dimensions,Describe feature recurrence assessment method,Specify total number of covariates included",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,Not reported,Starting and adhering (PP),Composite RR 0.99,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Risk of Pneumonia in New Users of Cholinesterase Inhibitors for Dementia,Done,27/4/2015,10.1111/jgs.13380,Yes,USA,Public,Not reported,,Not reported,1,Medicare,Medicaid or Medicare,PCD,USA,Safety,"ITT,Per-protocol",1,pneumonia,Time to event,4,1,Neurology,Galantamine,Pharmacological,N06DA04,Active comparator,donepezil,New-user design,Not reported,Not reported,hdPS,No,Sensitivity analysis,,,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,,,,Schneeweiss citation,,Not reported,Adjustment,,No additional variables used with/before/after hdPS,No,Cox regression,1176,30174,Unclear,No,,,No,Not reported,,,Not reported,Specify software,Yes,Multivariable analysis on predefined variables,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.76,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Risk of preterm delivery and small-for-gestational age births in women with autoimmune disease using  biologics before or during pregnancy: a population- based cohort study,Done,1/3/2018,10.1136/annrheumdis-2018-213023,Yes,Canada,Public,Not reported,,Not reported,1,Population Data BC,British Columbia health databases,PCD,Canada,Safety,ITT,2,preterm delivery / SGA birth,Binary,1,1,Rheumatology,any biologics,Pharmacological,L04A,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,4,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient diagnoses,Disease specific",Perinatal registry,ICD-10,,Other,"3 digit ICD,Other",,,,"""Once, sporadic, frequent""",Bross formula,23,50,No,Logistic regression,,Not reported,Matching,"Adjustment,Adjustment on deciles (stratification)",No additional variables used with/before/after hdPS,Yes,Logistic regression,134,8440,Yes,No,109,584,Yes,Standardized Difference,,,Not reported,"Specify data dimensions,Specify software,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.13,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis,Done,18/4/2017,10.1093/rheumatology/kex049,Yes,USA,Public,Not reported,,Not reported,1,MarketScan,Truven Marketscan,PCD,USA,Safety,Per-protocol,1,first occurrence of a ser- ious bacterial infection,Time to event,1,1,Rheumatology,TNFi,Pharmacological,L04AB,Active comparator,DMARD,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,182,"Outpatient diagnoses,Inpatient diagnoses,Outpatient procedures (including tests),Inpatient procedures (including tests),Outpatient drug dispensation",,Other,Other,Generic drug names,"Other,Generic drug name",,,,Schneeweiss citation,Schneeweiss citation,8,500,No,Logistic regression,,Not reported,Matching,,No additional variables used with/before/after hdPS,Yes,Cox regression,482,2013,No,Yes,482,2013,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,"SAS,Stata",Starting and adhering (PP),HR 2.65,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Risk of sudden cardiac arrest  and ventricular arrhythmia with  sulfonylureas: An experience with  conceptual replication in two  independent populations,Done,22/6/2020,10.1038/s41598-020-66668-5,Yes,USA,Public,Not reported,,Not reported,2,Medicaid / Optum,"Medicaid or Medicare,Optum Clinformatics",PCD,USA,Safety,Per-protocol,1,SCA/VA event,Time to event,2,1,Diabetology,glimepiride,Pharmacological,A10BB12,Active comparator,glipizide,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient drug dispensation,Outpatient procedures (including tests),Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests)",,"ICD-10,ICD-9",CPT,Generic drug names,"3 digit ICD,5 digit CPT,Generic drug name",,Yes,200,Schneeweiss citation,Bross formula,55,427,Unclear,Logistic regression,,Not reported,Adjustment,,To adjust after hdPS matching/weighting,Yes,Cox regression,124354,268094,No,No,124354,268094,No,Standardized Difference,,Surveillance for IVs,Yes,"Specify data dimensions,Describe results of diagnostics and sensitivity analysis,Specify software,Specify total number of covariates included,Specify covariate priorisation method,Description parameters for feature generation",No,,,Not reported,Not reported,On demand,SAS,Starting and adhering (PP),HR 1.17,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Secondary prevention of acute coronary syndrome with antiplatelet agents in real life: A high-dimensional propensity score matched cohort study in the French National claims database,Done,7/12/2018,10.1016/j.atherosclerosis.2018.11.037,Yes,France,Private,Yes,EUPAS / CT.GOV,Available,1,SNDS,SNDS,PCD,France,Both,Per-protocol,4,death / hospital admission for ACS / stroke / bleeding,Time to event,2,2,Cardiology,clopidogrel,Pharmacological,B01AC04 ,Active comparator,ticagrelor,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Inpatient diagnoses,Medical encounters,Outpatient diagnoses,Disease specific",LTD / specific drugs,ICD-10,,ATC,"3 digit ICD,Other",ATC 7 digits,,,"""Once, sporadic, frequent""",Association with outcome,11,160,No,Logistic regression,,Not reported,Matching,Adjustment,To match with the hdPS,Yes,Cox regression,19796,13916,Yes,Yes,9224,9224,Yes,Standardized Difference,,PS distribution plots,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.88,Moderate,Low,Low,Serious,NI,Low,Moderate,Serious
"Sentinel Modular Program for Propensity-Score Matched Cohort  Analyses: Application to Glyburide, Glipizide, and Serious  Hypoglycemia",Done,30/6/2017,10.1097/EDE.0000000000000709,Yes,USA,Public,Not reported,,Not reported,1,Sentinel Distributed Database,Other,Both linked,USA,Safety,Per-protocol,1,Serious hypoglycemia,Time to event,1,1,Diabetology,Glyburide,Pharmacological, A10BB01,Active comparator,Glipizide,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient drug dispensation,Inpatient diagnoses,Inpatient procedures (including tests),Outpatient procedures (including tests)",,ICD-9,"CPT,HCPCS",Not reported,,,,,Schneeweiss citation,Association with exposure,12,200,Unclear,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,198553,379508,Yes,No,116641,116641,No,Standardized Difference,,"PS distribution plots,Inspection of selected variables",Not reported,"Specify data dimensions,Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.51,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Sequential Monitoring of the Comparative  Effectiveness and Safety of Dabigatran in  Routine Care,Done,1/2/2019,10.1161/CIRCOUTCOMES.118.005173,Yes,USA,Private,Not reported,,Not reported,2,MarketScan / Clinformatics,"Optum Clinformatics,Truven Marketscan",PCD,USA,Both,"Per-protocol,ITT",2,hospitalization for stroke / major bleeding,Time to event,1,1,Cardiology,dabigatran,Pharmacological,B01AE07,Active comparator,warfarine,New-user design,Not reported,Not reported,hdPS,No,Sensitivity analysis,,,Unclear,,,,,,,,,Schneeweiss citation,Bross formula,78,,Unclear,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,6961,19975,Unclear,No,,,No,"Standardized Difference,C-statistic",,,Not reported,Specify covariate priorisation method,Yes,Propensity score with predefined variables,,RECORD-PE,Not reported,Not reported,Not reported,Starting and adhering (PP),HR 0.68,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI A Cohort Study of Eight Administrative Databases and Meta-Analysis,Done,1/10/2015,10.2215/CJN.11271114,Yes,Canada,Public,Not reported,,Mentioned but not available,8,CNODES databases / CPRD / MarketScan,"CNODES network databases,CPRD (+HES),Truven Marketscan","PCD,EMR / Registry",Canada / UK / USA,Safety,ITT,1,hospitalization with a diagnosis of AKI,Time to event,1,1,Psychiatry,SNRI,Pharmacological,N06AX,Active comparator,SSRI,Other,Not reported,Not reported,hdPS,No,Primary analysis,,365,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,4,500,No,Logistic regression,,Yes,Adjustment on deciles (stratification),,To adjust with hdPS (stratas or not),No,Logistic regression,,,Unclear,No,,,No,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),RR 0.85,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Sodium‐glucose co‐transporter 2 inhibitors and the risk of fractures: A propensity score‐matched cohort study,Done,1/9/2019,10.1002/pds.4900,Yes,USA,Not reported,Not reported,,Not reported,1,MarketScan,Truven Marketscan,PCD,USA,Safety,"Per-protocol,ITT",1,first occurrence of any non ‐vertebral fracture,Time to event,1,1,Diabetology,SGLT2i,Pharmacological,A10BK,Active comparator,DPP4i,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Outpatient diagnoses,Inpatient procedures (including tests),Outpatient procedures (including tests),Inpatient diagnoses,Outpatient drug dispensation",,Not reported,Not reported,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,18,500,No,Schneeweiss citation,,Not reported,Matching,,,No,Cox regression,34352,99641,Yes,Yes,30549,30549,No,"Standardized Difference,C-statistic",,PS distribution plots,Not reported,"Specify data dimensions,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,Not reported,"SAS,Stata",Starting and adhering (PP),HR 1.11,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Statin potency and the risk of hospitalization for community-acquired pneumonia,Done,23/11/2016,10.1111/bcp.13208,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK + HES,Safety,ITT,1,HCAP,Binary,1,1,Cardiology,High  potency statin,Pharmacological,C10AA,Active comparator,Lower potency statin,Other,Not reported,Not reported,hdPS,No,Primary analysis,,,,,,,,,,,,Schneeweiss citation,Bross formula,9,500,Unclear,Schneeweiss citation,,Not reported,Adjustment on deciles (stratification),,To adjust with hdPS (stratas or not),No,Logistic regression,217721,130707,Unclear,,,,Yes,C-statistic,,,Not reported,"Specify covariate priorisation method,Specify total number of covariates included,Specify software",Yes,Multivariable analysis on predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),1.14,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Suicide death over the first year of lithium versus valproate treatment in  cohorts with and without bipolar disorder,Done,15/12/2021,10.1016/j.jpsychires.2021.12.011,Yes,USA,Public,Not reported,,Not reported,1,Veterans Health Administration,Veterans Administration databases,PCD,USA,Efficacy,ITT,1,Suicide death,Time to event,1,1,Psychiatry,lithium,Pharmacological,N05AN,Active comparator,valproate,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,1,,Other,,,,,,,No,,None,No prioritization,,917,No,Logistic regression,,,Matching,,,No,Cox regression,11966,28198,Yes,No,11649,11649,No,Standardized Difference,,,Yes,"Specify software,Specify total number of covariates included,Describe feature recurrence assessment method,Specify data dimensions,Description parameters for feature generation,Specify covariate priorisation method",No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 1.50,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population‐based cohort study,Done,17/6/2019,10.1111/bcp.14056,Yes,Canada,Private,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Both,"Per-protocol,ITT",1,myocardial infarction,Time to event,1,1,Diabetology,sulfonylurea,Pharmacological,A10BB,Active comparator,metformin,New-user design,Not reported,No,hdPS,No,Primary analysis,,,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,38,500,Unclear,Schneeweiss citation,,Yes,Matching,,No additional variables used with/before/after hdPS,Unclear,Cox regression,77138,17612,Yes,Yes,13999,13999,No,Standardized Difference,,PS distribution plots,Not reported,Specify total number of covariates included,No,,,Not reported,Not reported,Not reported,Not reported,Starting and adhering (PP),HR 1.04,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia,Done,12/10/2017,10.1016/j.amjmed.2017.09.044,Yes,Canada,"Public,Private",Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Safety,Per-protocol,1,severe hypoglycemia,Time to event,1,1,Diabetology,sulfonylurea,Pharmacological,A10BB,Active comparator,metformin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,7,365,"Outpatient prescriptions,Outpatient procedures (including tests),Outpatient diagnoses,Inpatient diagnoses,Inpatient procedures (including tests),Administrative data",administrative information / disease history,,,,,,,,Schneeweiss citation,Schneeweiss citation,39,500,No,Schneeweiss citation,,Not reported,Matching,,No additional variables used with/before/after hdPS,No,Cox regression,17612,77138,Yes,Yes,14012,14012,Yes,Standardized Difference,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 4.53,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
Sulfonylureas as second line drugs in type 2 diabetes and the  risk of cardiovascular and hypoglycaemic events: population  based cohort study,Done,11/6/2018,10.1136/bmj.k2693,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD + HES + ONS,CPRD (+HES),Both linked,UK,Safety,Per-protocol,5,hospital admission for myocardial infarction / cardiovascular death / all-cause mortality / severe hypoglycaemia,Time to event,1,1,Diabetology,sulfonylurea,Pharmacological,A10BB,Active comparator,metformin,Prevalent new user,Not reported,Not reported,hdPS,No,Primary analysis,7,365,"Outpatient prescriptions,Procedures (all),Outpatient diagnoses,Diagnoses (all),Inpatient diagnoses,Administrative data",administrative / disease history,"Read Codes,ICD-10",Other,Other,,,,,Schneeweiss citation,Bross formula,,500,No,Logistic regression,,Yes,Matching,,"To match with the hdPS,To adjust after hdPS matching/weighting",No,Cox regression,25699,51439,Yes,Yes,23551,23551,No,Standardized Difference,,,Not reported,"Specify total number of covariates included,Specify software,Specify data dimensions,Specify covariate priorisation method",Yes,Negative controls,,Not reported,Not reported,Not reported,"SAS,R",Starting and adhering (PP),HR 1.26,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease,Done,8/9/2019,10.1093/ndt/gfz167,Yes,Canada,Public,Not reported,,Mentioned but not available,1,ICES,Ontario health databases,PCD,Canada,Both,"Per-protocol,ITT",1,all-cause mortality,Time to event,1,1,Cardiology,beta-blocker,Pharmacological,C07A,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,365,Unclear,,,,,,,,,Schneeweiss citation,Bross formula,,,No,Schneeweiss citation,,Not reported,Matching,,To match with the hdPS,No,Cox regression,7706,20071,Yes,Yes,5862,5862,No,Standardized Difference,,,Not reported,"Specify covariate priorisation method,Specify software",No,,,RECORD,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.58,Moderate,Low,Low,Moderate,NI,Low,NI,Moderate
The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death,Done,1/4/2015,10.1016/j.jcjd.2015.02.002,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD + HES,CPRD (+HES),Both linked,UK,Both,Per-protocol,1,"Composite MI, stroke, all-cause mortality",Time to event,1,1,Diabetology,DPP4i + metformin,Pharmacological,A10B,Active comparator,Sulfonylurea + metformin,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,,"Drugs (all),Procedures (all),Diagnoses (all),Administrative data",prescriptions / procedures / diagnoses / disease history / administrative information,"ICD-10,Read Codes",Not reported,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,9,200,Yes,Schneeweiss citation,,Not reported,Stratification,,No additional variables used with/before/after hdPS,No,Cox regression,2299,10341,Yes,Yes,2286,9521,Yes,Not reported,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 0.62,Serious,Moderate,Low,Serious,NI,Low,NI,Serious
The Potential of High-Dimensional Propensity Scores in Health Services Research: An Exemplary Study on the Quality of Care for Elective Percutaneous Coronary Interventions,Done,16/1/2017,10.1111/1475-6773.12653,Yes,Germany,Public,Not reported,,Not reported,1,GePaRD,GePaRD,PCD,Germany,Both,ITT,1,Mortality,Time to event,1,1,General Surgery,Inpatient PCI,Not-pharmacological,,Active comparator,Outpatient PCI,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,6,365,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests),Outpatient prescriptions",,ICD-10,Other,"ATC,Other",3 digit ICD,,Yes,200,"""Once, sporadic, frequent""",Bross formula,40,500,No,Logistic regression,,Yes,Weighting,Matching,No additional variables used with/before/after hdPS,No,Cox regression,4269,26044,Yes,Yes,3964,7668,Yes,Standardized Difference,Different total number of covariates,Sequential addition of variables plots,Not reported,"Specify data dimensions,Description parameters for feature generation,Describe feature recurrence assessment method,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR 0.95,Moderate,Moderate,Low,Low,NI,Low,NI,Moderate
The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study,Done,16/12/2017,10.1016/j.diabres.2017.12.008,Unclear,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Safety,Per-protocol,1,time to the first diagnosis of fragi- lity fracture,Time to event,1,3,Diabetology,DPP-4 inhibitors,Pharmacological,A10BH,Active comparator,sulfonylureas,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,365,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,26,40,No,Schneeweiss citation,,Yes,Adjustment on deciles (stratification),Matching,,No,Cox regression,7998,27486,Yes,Yes,7993,26636,Yes,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,R,Starting and adhering (PP),HR 0.80,Moderate,Low,Low,Serious,NI,Low,NI,Serious
The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety,Done,25/2/2020,10.1186/s12933-020-00999-5,Yes,USA,Public,Not reported,,Mentioned but not available,2,Medicaid / Optum,"Medicaid or Medicare,Optum Clinformatics",PCD,USA,Safety,Per-protocol,1,incident outpatient-originating SCA/VA,Time to event,1,,Diabetology,rosiglitazone,Pharmacological,A10BG02,Active comparator,pioglitazone,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,10,365,"Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests),Outpatient drug dispensation,Lab records (all)",,"ICD-10,ICD-9","CPT,Other",Generic drug names,"3 digit ICD,5 digit CPT,Generic drug name,Other",,Yes,200,Schneeweiss citation,Bross formula,60,500,No,Logistic regression,,Not reported,Matching,,No additional variables used with/before/after hdPS,Yes,Cox regression,205767,297324,Yes,No,189799,189799,Yes,Standardized Difference,Different total number of covariates,PS distribution plots,Yes,"Specify data dimensions,Description parameters for feature generation,Specify covariate priorisation method,Specify total number of covariates included,Describe results of diagnostics and sensitivity analysis,Specify software",No,,,Not reported,Not reported,On demand,SAS,Assignment (ITT),HR 0.91,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Tofacitinib Persistence in Patients with Rheumatoid Arthritis:  A Retrospective Cohort Study,Done,16/4/2020,10.3899/jrheum.191252,Yes,Canada,Public,Not reported,,Not reported,1,IBM MarketScan,Truven Marketscan,PCD,USA,Efficacy,"ITT,Per-protocol",1,Discontinuation or swich,Time to event,1,1,Rheumatology,Tofacitinib,Pharmacological,L04AA29,Active comparator,bDMARD,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,5,365,"Outpatient drug dispensation,Outpatient diagnoses,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests)",,,,,,,,,Schneeweiss citation,Schneeweiss citation,,,No,Schneeweiss citation,,Yes,Adjustment on deciles (stratification),,To adjust with hdPS (stratas or not),No,Cox regression,1031,17803,Yes,No,,,Yes,Not reported,,,Not reported,Specify data dimensions,No,,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),HR 1.14,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Tramadol Use and the Risk of Hospitalization for Hypoglycemia in Patients With Noncancer Pain,Done,1/2/2015,10.1001/jamainternmed.2014.6512,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD + HES,CPRD (+HES),Both linked,UK,Safety,ITT,1,hospitalization for hypoglycemia,Time to event,1,1,Pain medicine,Tramadol,Pharmacological,N02AX02,Active comparator,Codeine,Other,Not reported,Not reported,hdPS,No,Secondary analysis,7,365,"Outpatient prescriptions,Outpatient procedures (including tests),Inpatient diagnoses,Inpatient procedures (including tests),Outpatient diagnoses,Administrative data",disease history / administrative information ,"ICD-10,Not reported",Not reported,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,41,500,No,Logistic regression,,Not reported,Adjustment on deciles (stratification),,No additional variables used with/before/after hdPS,No,Cox regression,28110,305924,Yes,Yes,28109,305862,Yes,C-statistic,,,Not reported,"Specify data dimensions,Specify total number of covariates included,Specify software",Yes,,Nested Case-Control Approach / Case-Crossover Approach,Not reported,Not reported,Not reported,SAS,Assignment (ITT),hospitalization for hypoglycemia HR 3.60,Moderate,Low,Low,Low,Low,Low,NI,Moderate
Tramadol versus codeine and the short-term risk of cardiovascular events in patients with non-cancer pain: A population-based cohort study,Done,13/9/2021,10.1111/bcp.15099,Yes,Canada,Public,Not reported,,Mentioned but not available,1,CPRD,CPRD (+HES),EMR / Registry,UK,Safety,ITT,1,hospitalization or death due to myocardial infarction,Time to event,1,1,General Practice,Tramadol,Pharmacological,N02AX02,Active comparator,Codeine,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,49,500,No,Schneeweiss citation,,Yes,Adjustment on deciles (stratification),Matching,,No,Cox regression,123394,914333,Yes,No,123390,913966,No,Standardized Difference,,,Not reported,Specify total number of covariates included,No,,,Not reported,Not reported,Not reported,Not reported,Assignment (ITT),HR 1.00,Moderate,Low,Low,Low,NI,Low,NI,Moderate
Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States,Done,13/6/2011,10.1053/j.ajkd.2011.03.026,Yes,USA,Public,Not reported,,Not reported,1,US Renal Data System,Other,EMR / Registry,USA,Efficacy,ITT,4,All cause mortality,Time to event,1,1,Nephrology,ICD implantation,Not-pharmacological,,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,,Unclear,,,,,,,,,Schneeweiss citation,Schneeweiss citation,33,,Unclear,Schneeweiss citation,,Not reported,Matching,,To adjust after hdPS matching/weighting,No,Cox regression,9528,,Yes,No,2232,8928,No,Not reported,,,Not reported,Specify software,No,,,Not reported,Not reported,Not reported,SAS,Assignment (ITT),HR ??,Moderate,Serious,Low,Serious,NI,Low,NI,Serious
Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States,Done,21/8/2013,10.1136/bmj.f4877,Yes,USA,Public,Not reported,,Not reported,1,Medicaid,Medicaid or Medicare,PCD,USA,Safety,ITT,1,postpartum hemorrhage,Binary,6,1,Psychiatry,currently exposed to SRI monotherapy,Pharmacological,N06AB ,Standard care,Unexposed,New-user design,Not reported,Not reported,hdPS,No,Primary analysis,,,Unclear,,Not reported,Not reported,Not reported,,,,,Schneeweiss citation,Schneeweiss citation,19,200,Unclear,Schneeweiss citation,,Yes,Adjustment,,No additional variables used with/before/after hdPS,No,Poisson regression,29222,69044,Yes,No,12203,53348,No,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",Yes,Propensity score with predefined variables,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.52,Moderate,Serious,Low,Serious,NI,Low,NI,Serious
"Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases",Done,20/3/2013,10.1136/bmj.f880,Yes,Canada,Public,Not reported,,Not reported,9,Alberta / British Columbia / Manitoba / Nova Scotia / Ontario / Quebec / Saskatchewa / MarketScan / CPRD,"CNODES network databases,Truven Marketscan,CPRD (+HES)","PCD,EMR / Registry",Canada / USA / UK,Safety,Per-protocol,1,"hospitalization for acute kidney injury,",Time to event,1,1,Cardiology,High potency statins,Pharmacological,C10AA,Active comparator,Low potency statins,Other,Not reported,Not reported,hdPS,No,Primary analysis,,365,,,,,,,,,,Schneeweiss citation,Schneeweiss citation,10,500,No,Logistic regression,,Not reported,Adjustment on deciles (stratification),,"To adjust with hdPS (stratas or not),To match before the hdPS",Unclear,Logistic regression,,,Unclear,No,,,No,Not reported,,,Not reported,"Specify total number of covariates included,Specify software",No,,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),0.97,Moderate,Low,Low,Serious,NI,Low,NI,Serious
Use of Leukotriene Receptor Antagonists Are Associated with a  Similar Risk of Asthma Exacerbations as Inhaled Corticosteroids,Done,25/7/2014,10.1016/j.jaip.2014.05.009.,Yes,USA,Public,Not reported,,Not reported,2,PEAL Network / TennCare Medicad,"Medicaid or Medicare,Other US commercial","PCD,Both linked",USA,Efficacy,Per-protocol,4,asthma-related ED visit / hospitalization / fill of oral corticosteroids / composite,Time to event,2,1,Pulmonary Medicine,leukotriene antagonists,Pharmacological,R03DC,Active comparator,ICS,New-user design,Not reported,Not reported,hdPS,No,Secondary analysis,7,365,"Outpatient drug dispensation,Outpatient diagnoses,Inpatient procedures (including tests),Inpatient diagnoses,Outpatient procedures (including tests),Other",Emergency department procedure / diagnoses,,,,,,,,Schneeweiss citation,Schneeweiss citation,7,,No,Logistic regression,,Not reported,Adjustment,,No additional variables used with/before/after hdPS,No,Cox regression,5867,4022,No,No,,,No,Not reported,,,Not reported,"Specify data dimensions,Specify software",Yes,Multivariable analysis on predefined variables,,Not reported,Not reported,Not reported,SAS,Starting and adhering (PP),HR 1.10,Moderate,Low,Low,Serious,NI,Low,NI,Serious